Published in final edited form as:

Hum Genet. 2012 June ; 131(6): 877–901. doi:10.1007/s00439-011-1122-6.

Genetics of schizophrenia and smoking: an approach to studying their comorbidity based on epidemiological findings

Jose de Leon and

University of Kentucky Mental Health Research Center at Eastern State Hospital, 627 West Fourth St., Lexington, KY 40508, USA jdeleon@uky.edu

Department of Psychiatry, Institute of Neurosciences, University of Granada, Granada, Spain

Francisco J. Diaz

Department of Biostatistics, The University of Kansas Medical Center, Kansas City, KS, USA

Abstract

The association between schizophrenia and tobacco smoking has been described in more than 1,000 articles, many with inadequate methodology. The studies on this association can focus on: (1) current smoking, ever smoking or smoking cessation; (2) non-psychiatric controls or controls with severe mental illness (e.g., bipolar disorder); and (3) higher smoking frequency or greater usage in smokers. The association with the most potential for genetic studies is that between ever daily smoking and schizophrenia; it may reflect a shared genetic vulnerability. To reduce the number of false-positive genes, we propose a three-stage approach derived from epidemiological knowledge. In the first stage, only genetic variations associated with ever daily smoking that are simultaneously significant within the non-psychiatric controls, the bipolar disorder controls and the schizophrenia cases will be selected. Only those genetic variations that are simultaneously significant in the three hypothesis tests will be tested in the second stage, where the prevalence of the genes must be significantly higher in schizophrenia than in bipolar disorder, and significantly higher in bipolar disorder than in controls. The genes simultaneously significant in the second stage will be included in a third stage where the gene variations must be significantly more frequent in schizophrenia patients who did not start smoking daily until their 20s (late start) versus those who had an early start. Any genetic approach to psychiatric disorders may fail if attention is not given to comorbidity and epidemiological studies that suggest which comorbidities are likely to be explained by genetics and which are not. Our approach, which examines the results of epidemiological studies on comorbidities and then looks for genes that simultaneously satisfy epidemiologically suggested sets of hypotheses, may also apply to the study of other major illnesses.

Introduction

This article proposes a study approach to investigate the genetics of the association between schizophrenia and tobacco smoking based on results from the epidemiological literature. After an introduction, a short section that summarizes the various types of published data follows. The next two sections describe the association of schizophrenia with higher frequency and with higher intensity of smoking. The section describing the proposed study approach is followed by two sections placing the association between schizophrenia and smoking in the context of other psychiatric comorbidities: the association between nicotine and alcohol addiction, and the association between nicotine and drug addiction. Then, a description of how our study approach may take advantage of these other comorbidities follows.

This introduction provides the genetic expert without expertise in psychiatry with information on (1) the size and quality of the literature on schizophrenia and smoking; (2) some epidemiological statistical concepts; (3) the concept of addiction; (4) the concept of nicotine addiction; (5) the genetics of nicotine addiction; (6) the association between schizophrenia and nicotine addiction; and (7) the concept of severe mental illness (SMI), which encompasses other illnesses besides schizophrenia that are also associated with nicotine addiction, particularly bipolar disorder and major depressive disorder.

Schizophrenia and tobacco smoking literature

The literature is full of articles on the association between smoking and schizophrenia. A PubMed search on “schizophrenia AND (smoking OR nicotine)” on July 6, 2011, produced 1,341 articles. If one is not an expert in this area, one would think that more than 1,000 published articles would provide a good understanding of this association. We propose in this article that, unfortunately, this is not the case. Many of the published articles include simplistic statements due to misinterpretation of statistical associations as causal relationships. Clinicians and basic scientists may not be aware of the limitations of the epidemiological approach and may not realize that many of the statements published in articles on the association between schizophrenia and smoking are wrong, according to basic epidemiological principles. As a matter of fact, it is possible that many of the articles on schizophrenia and smoking published in the 1990s in psychiatric journals would not currently be accepted for publication by epidemiological journals as they were originally published. Many of these published articles failed to account for cross-sectional studies’ inability to establish causation and did not correct the reported statistical associations for confounding effects using multivariate statistics. Another problem with the information provided in the review sections of published articles on schizophrenia and smoking is that some authors frequently tend to ignore studies that do not fit their hypotheses and do not give proper weight to consistently replicated findings when describing the literature. As described by Ioannidis (2005), the medical literature is full of false findings due to the publication of significant but small effects observed in small samples. The most important factor in establishing a scientific finding in medicine is the finding’s replication across many independent samples. In particular, it is necessary that the finding survives the variations typically associated with the “noise” present in clinical research. In this regard we are quite confident that the association of schizophrenia with tobacco smoking is a “true” finding since it is a finding that has been consistently replicated all over the world (de Leon and Diaz 2005). However, we are not sure that many of the other findings published in the context of schizophrenia and smoking research are trustworthy, since very few have been consistently replicated. Thus, simplistic statements such as “smoking improves negative symptoms or antipsychotic side effects in schizophrenia patients” are not supported by a comprehensive review of the limited literature available (de Leon et al. 2006).

Epidemiological and statistical concepts

In this article two statistical measures are used to explore associations: adjusted odds ratios (ORs), and population attributable risks (PAR) calculated with these ORs (Bolton and Robinson 2010; Greenland and Drescher 1993). The OR is a measure of the strength of the association between two dichotomous variables: the more different from 1 an OR is, the stronger the association. When the 95% confidence intervals (CIs) of two ORs do not overlap, they are usually considered to be significantly different. Multivariate logistic regression allows adjusting ORs for potentially confounding variables. Once we have an adjusted OR, if we assume that the OR measures a causal relationship between a condition and a risk factor which is not explained by confounders, the PAR estimates the percentage reduction in the condition’s prevalence that would be observed if the risk factor were removed from the population.

Addiction

This article uses the term “addiction” to express the compulsive nature of taking an addictive drug (Volkow and Fowler 2000). Drug addiction is a group of chronically relapsing disorders characterized by compulsion to take the drug, loss of control in limiting the intake, and emergence of negative emotional states when there is no access to the drug (Koob and Volkow 2010). The current official psychiatric diagnostic system in the US is called the Diagnostic and Statistical Manual of Mental Disorders and is a variation of the third edition published in 1980, called DSM-III (American Psychiatric Association 1980). The current edition of the DSM continues to use the terminology “substance use disorder”, distinguishing between abuse (pathological use) and dependence (more severe pathological use with withdrawal symptoms).

The third and subsequent DSM editions use the word “substances” to mean “nicotine”, “alcohol”, and other substances of abuse that are usually included under the name “drugs”. The term “drug” usually refers to “illegal drugs” or prescribed drugs used inappropriately. Thus, this article, unless it is specifically needed (e.g., “nicotine dependence”, which is specifically defined) uses the terms “alcohol addiction”, “nicotine addiction” and “drug addiction” (referring to drugs other than nicotine or alcohol). When we use the plural word “addictions”, we mean addiction to any of these substances (nicotine, alcohol or other drugs) in general.

For researchers interested in genetics, it is important to know that addiction heritability estimates are 40–60% (Volkow and Li 2005) or 50–60% (Bierut 2011). Bierut (2011) recently described genetic vulnerability to addiction as probably reflecting the combination of hundreds or thousands of genes of modest effects. A complex issue not completely resolved by the literature is that genetic factors influencing the use of drugs may be different from those influencing addiction. Twin studies suggest that initiation and early patterns of drug use are strongly influenced by social and familial environmental factors whereas later patterns of use and levels of addiction are strongly influenced by genetic factors (Kendler et al. 2008). Even if we accept the hypothesis that genetic factors may be much more influential in drug addictions than in drug use, an explanation of the important role of genetic influences on addictions continues to be complex. A biological hypothesis proposes that genetic factors are expressed once exposed to sufficient quantities of the drug over a sufficiently long period. The socially mediated hypothesis is based on the finding that our genes play an increasing role in shaping our own social environment; it proposes that genes may influence the selection of environments that either actively discourage or encourage drug use (Kendler et al. 2008).

As this article focuses on the role of genetics in the association between schizophrenia and nicotine addiction, a context for the genetic studies on the association between psychiatric disorders and addictions is in order. In a very comprehensive approach, Kendler et al. (2003, 2007) proposed a model that posits (1) the pattern of lifetime comorbidity of common psychiatric disorders and addictions results largely from the effects of genetic risk factors, and (2) each addiction may have disorder-specific genetic risks.

Nicotine addiction

Epidemiological studies in the 1980s and 1990s in the US and other Western countries established that the majority of smokers in these general populations smoke at least one cigarette per day; that is, they are daily smokers. Few people in the general population of Western countries are considered occasional smokers. Nicotine is the most important addictive component of tobacco smoke. Thus, daily smoking is usually considered a sign of nicotine addiction. In the general population, initiation of daily smoking rarely occurs in the

decade of one's 20s (Nelson and Wittchen 1998; de Leon et al. 2002a; Dierker et al. 2008). Occasional smokers do not smoke daily, appear not to have major problems (no major withdrawal signs) when they do not smoke and, therefore, are not addicted (Shiffman 1989). "Daily smoking" is a simple and reasonable measure of nicotine addiction in epidemiological studies in Western countries.

In underdeveloped countries, few individuals can afford daily smoking and non-daily smokers need to be included in smoking studies; socioeconomic status needs to be carefully considered as well (Campo-Arias et al. 2006). In the US population, progressively greater smoking restrictions have been implemented since 2000. This has led to an increase in the proportion of non-daily smokers, who now account for one-third of the US smokers in the general population (Shiffman 2009). Therefore, Shiffman (2009) has proposed that heavy daily smoking may only occur when smoking is not constrained by economic, social, or legal restrictions.

The DSM, which has become widely used internationally since its third edition (DSM-III), does not list "nicotine abuse" as a possible diagnosis; only "nicotine dependence" is listed. Thus, the abuse and dependence concepts of this classificatory system have never particularly "worked well" for nicotine addiction. The reasons may be that (1) when compared with other drugs, nicotine is a particularly addictive substance (Henningfeld et al. 1991; Lopez-Quintero et al. 2011); and (2) it is a legal substance whose uncontrolled use is very rarely associated with legal complications. In a large US epidemiological study, Lopez-Quintero and coworkers (2011) estimated that 68% of nicotine users become dependent (vs. 23% for alcohol, 21% for cocaine, and 9% for cannabis users). The DSM concepts of nicotine dependence, however, have been used in a few epidemiological studies of the general population but not in patients with schizophrenia.

Clinicians and researchers working in smoking cessation frequently use a scale to define nicotine dependence. The Fagerström Test for Nicotine Dependence (FTND) is the most widely used measure of nicotine dependence, which has been found to be a reasonable predictor of success in stopping smoking (Heatherton et al. 1991). This scale has six items. However, two of the six items, which are each scored between 0 and 3, may reflect nicotine dependence best: Item 1 (the time between waking and smoking the first cigarette of the day), and Item 4 (the number of cigarettes smoked per day). The sum of the scores of these two items is called the Heaviness of Smoking Index (HSI) (Heatherton et al. 1998). A high FTND or HSI score appears to be a good indication of high nicotine dependence (de Leon et al. 2003; Diaz et al. 2005). Institutional smoking restrictions may artificially lower these scores (Steinberg et al. 2005).

Nicotine addiction and genetics

Genome-wide association studies (GWAS) have provided some robust findings for heavy smoking genetics in the 15q25 chromosome region, which encodes some nicotine receptor subunits (Bierut 2011). According to twin studies, heritability for smoking initiation has been estimated to be in males: 37% (Li et al. 2004), 31–61% (Tyndale 2003), and 22–75% (Rose et al. 2008) and in females: 55% (Li et al. 2004), 32–72% (Tyndale 2003), and 32–63% (Rose et al. 2008). Heritability for smoking persistence has been estimated to be in males: 59% (Li et al. 2004), and 50–71% (Tyndale 2003), and in females: 46% (Li et al. 2004), and 4–49% (Tyndale 2003).

Schizophrenia and nicotine addiction

Another unfounded statement, repeated by many articles, is that 80–90% of schizophrenia patients smoke (Chapman et al. 2009). A few studies conducted in the 1980s or 1990s from

Western countries, provided these very high prevalences. However, these studies are not representative of schizophrenia patients throughout the world and reflect a point in time when smoking was even used as reinforcement in psychiatric hospitals. Moreover, although we are convinced that the association of schizophrenia and smoking is very consistent across the world and that a biological explanation is likely to account for it, we have to acknowledge that, as with any other addictive drug, nicotine addiction in schizophrenia is obviously influenced by the availability of the drug. Therefore, the prevalence of tobacco smoking in a particular sample of schizophrenia patients is going to be influenced by the availability of tobacco in the particular place and time at which the sample is collected. Our review of 42 samples from 20 countries provided a combined prevalence of current smoking of 62%. More important than this average prevalence is the size of the association between schizophrenia and smoking when comparing schizophrenia patients with the general population, that is, the effect size. This effect size is measured by a meta-analysis' overall OR (and its CI), 5.3 (4.9–5.7) (de Leon and Diaz 2005). This estimated average OR is not a “true” and stable measure of the association. The worldwide average OR has to be recalculated as new studies reflect changes in smoking prevalences in the general population of each country, and changes in the access to tobacco of people who are going to develop schizophrenia (de Leon et al. 2007a).

The tobacco epidemic throughout the world usually passes through five stages (early, rising, peak, declining and late stages). Different countries are usually in different stages and women tend to be at earlier stages than men. Since many people from the US general population have quit smoking, the US is currently in the declining period. Low-income countries are currently in the early stages (Anderson 2006). People with schizophrenia tend to be somewhat isolated from smoking reduction trends (de Leon et al. 2002b) and, after more than 20 years of studies of people with schizophrenia in several Western countries, most of our studies reflect very low rates of smoking cessation (<20%) in schizophrenia patients under naturalistic conditions (i.e., without treatment), which are probably typical in the majority of psychiatric settings. Only in our most recently published study of psychosis and smoking have we seen prevalences of smoking cessation >20% in psychotic patients (60% in males and 28% in females). This study included Spanish patients in their early stages of psychosis who were followed for 8 years (González-Pinto et al. 2011).

Association between SMIs and addictions

The concept of SMI usually includes schizophrenia and severe mood disorders (bipolar disorder and major depressive disorder), and may encompass nearly 3% of the US population in a 1-year period (National Advisory Mental Health Council 1993). In the US, people with schizophrenia and severe mood disorders are frequently treated in the public health system.

Based on our epidemiological approach, we proposed that a shared genetic vulnerability model may explain the high prevalence of smokers among people with schizophrenia (de Leon 1996). As further data verified that this association is consistent throughout the world, and that the increase in smoking initiation starts before schizophrenia starts, we have come to firmly believe that the shared vulnerability definitively reflects a genetic component (de Leon and Diaz 2005). From a different perspective which considers neurobiological data, Freedman et al. (1997) defended the view that this association may be explained by an association of schizophrenia with genetic variations in the $\alpha 7$ nicotine receptor gene. This genetic explanation has not been empirically confirmed but, more recently, Freedman and coworkers found abnormalities in the expression of these receptors in schizophrenia nonsmokers who were compared with controls; the abnormalities were not present in schizophrenia smokers (Mexal et al. 2010).

The self-medication hypothesis suggests that patients with SMIs select specific drugs to treat their psychiatric symptoms (Khantzian 1985). Schizophrenia patients usually get addicted to nicotine before their illness starts; thus it does not seem plausible that schizophrenia patients get addicted to nicotine to treat their illness. However, we cannot rule out the possibility that in some patients and in some circumstances patients who are smokers may smoke more to decrease symptoms or side effects such as akathisia (de Leon et al. 2006). Other reviews have also been critical of the self-medication hypothesis (Ziedonis et al. 2008). Prochaska et al. (2008) suggested that the tobacco industry's support for this hypothesis may explain why it has remained so popular in the literature and why other hypotheses have received less attention.

Study designs for exploring smoking behaviors in schizophrenia

This section focuses on two major issues that are crucial for designing studies of the association between schizophrenia and smoking: the definition of smoking behaviors and the selection of controls.

Defining smoking behaviors

In a simplified way, the association between schizophrenia and tobacco smoking can mean (1) the frequency of smokers is higher in schizophrenia patients than in other people ("a higher percentage of them smoke") and/or (2) schizophrenia smokers smoke more cigarettes daily than other smokers ("they smoke more cigarettes"). More precise meanings can be given by using testable hypotheses that compare schizophrenia patients with controls as follows: (1) "schizophrenia is associated with an increase in smoking", and (2) "schizophrenia is associated with increased smoking among smokers".

Those interested in genetics should know that the genetics of current daily smoking may not be a good study target. Current daily smoking reflects two addiction processes: (1) ever being addicted (or ever daily smoking), and (2) addiction persistence (lack of smoking cessation in ever daily smokers). Thus the association between schizophrenia and current daily smoking may not be particularly useful for those interested in completing genetic studies of schizophrenia and nicotine addiction. More interesting facts are the statistical association of schizophrenia with increased frequencies of ever daily smoking, and with decreased smoking cessation among ever daily smokers.

Selection of controls

Regarding studying control subjects, two major types of controls can be selected: non-psychiatric controls representing the general population and patients with other SMIs. Patients with other SMIs are a better comparison group than the general population in studies of schizophrenia patients. It is well established that psychiatric disorders are associated with high frequencies of smoking (Hughes et al. 1986; Covey et al. 1994; Lasser et al. 2000). This is particularly true for people with SMIs other than schizophrenia such as major depressive disorder or bipolar disorder, who exhibit greater frequencies of smoking than non-psychiatric controls in all large US epidemiological studies (Covey et al. 1994; Lasser et al. 2000; McClave et al. 2010). It is not surprising that only a few studies use patients with other SMIs since these studies usually have much less statistical power than studies using non-psychiatric controls. In a 2007 US survey the difference in age-adjusted prevalences of current smoking between schizophrenia and bipolar disorder was 12.7% ($=59.1 - 46.4$); in contrast, a difference of 40.8% ($=59.1 - 18.3$) between schizophrenia patients and non-psychiatric controls was observed (McClave et al. 2010).

Schizophrenia is associated with more smokers

This section focuses on the design of studies probing schizophrenia's association with more smokers. Six types of studies are possible, including those focused on (1) an increase in current smoking with respect to the general population; (2) an increase in current smoking with respect to other SMIs; (3) an increase in ever smoking with respect to the general population; (4) an increase in ever smoking with respect to other SMIs; (5) a decrease in smoking cessation in smokers with respect to the general population; or (6) a decrease in smoking cessation in smokers with respect to other SMIs.

Schizophrenia is associated with an increase in current smoking when compared with the general population

As described above, the prevalences of smoking in the general population vary across time and space. They also vary across schizophrenia patient samples, but perhaps less. Thus, it is more important to focus on effect sizes, quantifying the difference in prevalences between schizophrenia patients and controls and its stability. Our meta-analysis showed a very strong association between schizophrenia and current smoking ($OR = 5.3$) (see Table 1). Was this association consistent across countries? Yes, 40 of the 42 reviewed studies showed a significant association in the same direction ($OR > 1$, i.e., a smoking frequency higher in schizophrenia). Only two studies provided an $OR < 1$: a Colombian study also showing a low prevalence of smoking in the general population (Suárez et al. 1996), and a Japanese study with high smoking prevalences (Mori et al. 2003). These two studies reflect a “floor effect” and a “ceiling effect”, respectively. The association between schizophrenia and current smoking cannot be found if nobody smokes in the general population (0%, the floor), or if everybody smokes (100%, the ceiling). Based on our experience reviewing worldwide studies (de Leon and Diaz 2005), the floor and ceiling effects may occur at about 20 and 60% of current smoking in the general population, respectively (de Leon et al. 2007a). Thus, when only 20% of the population are current smokers, it is difficult to find an association unless confounding variables such as gender or educational (or socioeconomic) status are carefully controlled for and large samples are used. A Colombian schizophrenia sample that showed no significant differences when compared with published rates for the general population (Campo et al. 2004) became significantly different when compared with matched controls ($OR = 3.1$, $CI\ 1.4-6.8$) (Campo-Arias et al. 2006). At the time of the negative Japanese study (Mori et al. 2003), few women smoked (13%) and many males smoked (60%) in the Japanese general population. Thus, the Japanese schizophrenia study that did not show an association between smoking and schizophrenia (Mori et al. 2003) was contaminated by using published general population rates and not controlling for confounders and gender differences. In fact, in that Japanese study, schizophrenia females smoked significantly more than the general population (de Leon and Diaz 2005), and the association between schizophrenia and smoking in male smokers was limited by the ceiling effect of the male Japanese general population. A more recent Japanese study showed that after controlling for confounders it was also possible to demonstrate an association between schizophrenia and smoking in Japan (Shinozaki et al. 2010).

Changes in the smoking epidemic have been heavily influenced by gender and economic factors (Anderson 2006). To present a simplified version of the tobacco epidemic's chronology, it must be noted that in Western countries gender differences were obvious in the first half of the twentieth century since few females smoked, but the differences have decreased since then. In non-Western countries, female smoking continues to be rare but is increasing, and the bulk of the tobacco business appears to be moving to Asian males (Anderson 2006).

If one believes that gender differences in smoking are important, one needs to acknowledge that ORs using the general population as a control are poor measures of association unless they are adjusted for gender. Nonetheless, ORs stratified by gender may be the best way of describing the association between schizophrenia and current smoking throughout the world. In our meta-analysis, the overall male OR for current smoking was 7.2 (Table 1). More importantly, out of the 32 studies that provided male ORs, three provided ORs < 1; however, these three studies were conducted in non-Western countries, probably with ceiling effects. Samples matched for socioeconomic and educational status may be needed to detect the association in countries with ceiling effects. In the meta-analysis, the overall female OR was 3.3 (Table 1). Five of the 25 studies that provided female ORs provided ORs < 1. These studies were conducted in Western countries with floor effects; again, matched studies may be needed to detect the association (de Leon and Diaz 2005).

Schizophrenia may be associated with an increase in current smoking when compared with other SMIs

When comparing schizophrenia with other SMIs, our meta-analysis produced an overall OR of 1.9 (de Leon and Diaz 2005). The male OR was 2.3. The female OR was 1.8 but only 3 of 8 studies had significant ORs >1 (Table 1). Unfortunately, few of the studies comparing schizophrenia with other SMIs have controlled for other addictions. In Western countries, alcohol and drug addictions are strongly associated with current smoking. In the US and other Western countries, other addictions may also be associated with SMIs, in general, and with schizophrenia in particular. Thus, methodologically sound studies trying to establish the association between schizophrenia and smoking need to control for the confounding effects of gender and substance use disorders. Few published studies have controlled for these confounders (de Leon et al. 2002b, 2005).

Is schizophrenia associated with increased ever smoking when compared with the general population?

The meta-analysis' overall OR was 3.1 (de Leon and Diaz 2005). The male OR was 7.3 and the female OR was 2.8 (Table 1). The reviewed studies did not control for confounders such as level of education. In a more recent US study using ever daily smoking as a definition of ever smoking and non-psychiatric controls, there was a significant association of ever smoking with schizophrenia after controlling for confounders (OR = 5.2; CI 3.6–7.8) (de Leon et al. 2007a). This large OR may be partly explained by factors associated with schizophrenia that are not well controlled by using non-psychiatric controls (e.g., the presence of other addictions). Using the general population as a control does not allow the possibility of adjusting for other addictions since other addiction levels in the general population are low and, therefore, difficult to represent in general population samples.

By using survival analyses that were focused on age at onset of daily smoking and controlled for confounders, we have specifically explored the timing in the association of schizophrenia with an increased initiation of daily smoking in three studies (two in the US and one in Spain). The three studies (de Leon et al. 2002a; Gurpegui et al. 2005; Diaz et al. 2008) replicated that (1) when compared with non-psychiatric controls, schizophrenia was associated with a significant increase in initiation of ever daily smoking after controlling for education and gender; and (2) non-psychiatric smokers showed a pattern of getting addicted in their teens, with very few people getting addicted in their late 20s; in contrast, schizophrenia patients continue to be at risk of becoming addicted after the age of 20. By focusing only on people who started daily smoking 5 years before illness onset, two of the studies (Gurpegui et al. 2005; Diaz et al. 2008) demonstrated that the differences between schizophrenia patients and non-psychiatric controls were not explained by the prodromal effects of schizophrenia illness. A study of Chinese male schizophrenia patients replicated

the association of schizophrenia with increased initiation of daily smoking, by focusing on individuals who started to smoke 5 years before illness onset (Zhang et al. 2010).

Is schizophrenia associated with increased ever daily smoking when compared with other SMIs?

The meta-analysis overall OR was 2.0 and significant for the total and male samples but did not reach significance in female samples (Table 1). The average rates of lifetime smoking in schizophrenia patients were 69% for the total samples, 83% for males, and 65% for females (de Leon and Diaz 2005). These studies did not control for some confounders such as level of education and substance use disorders. In a more recent US study of ever daily smoking, there was a significant association of ever daily smoking with schizophrenia after controlling for confounders, OR = 1.9 (CI 1.2–2.8) (de Leon et al. 2007a).

Our survival analyses of age at onset of daily smoking which controlled for confounders suggest that severe mood disorders have an intermediate position between schizophrenia and non-psychiatric controls in the risk of becoming an ever daily smoker, but the sample sizes were not sufficient to establish a significant difference between schizophrenia and mood disorders (de Leon et al. 2002a; Diaz et al. 2008).

Is schizophrenia associated with decreased smoking cessation in ever smokers when compared with the general population?

The meta-analysis overall OR for lack of smoking cessation for the total samples of ever smokers was 5.3. The male and female ORs were 10.0 and 2.2, respectively (Table 1). These studies did not control for other confounders. In a more recent US study that defined smoking cessation as not smoking for 1 year after being an ever daily smoker, which used non-psychiatric controls, there was a significant association between schizophrenia and a lack of smoking cessation after controlling for confounders (OR = 5.6; CI 3.4–9.1) (de Leon et al. 2007a).

The stronger predictors of failing to quit smoking are probably heavy smoking and high nicotine dependence. As schizophrenia is strongly associated with heavy smoking and possibly with high nicotine dependence (see next section), the most reasonable explanation for the association between schizophrenia and lack of smoking cessation is the high levels of nicotine dependence in schizophrenia patients. Before considering genetic factors as a possible explanation for the decreased smoking cessation in smokers with schizophrenia, one needs to consider the association between schizophrenia and high nicotine dependence in smokers.

Naturalistic studies indicate that smoking cessation in schizophrenia smokers is low (<10 or 20%) when no special treatment is provided. Due to the high levels of dependence, intensive programs are needed to help schizophrenia patients to stop smoking (Ziedonis and George 1997). According to the clinical trials literature, the only interventions that have proven to be somewhat effective in reducing smoking in schizophrenia are bupropion and contingent reinforcement (Tsoi et al. 2010).

Is schizophrenia associated with decreased smoking cessation in ever smokers when compared with other SMIs?

The limited number of studies and their limited sample size make it difficult to draw any reliable conclusion about the association between smoking cessation and schizophrenia when comparing schizophrenia patients with other SMIs (Table 1). In the more recent and larger of our US studies, which used controls with other SMIs and defined smoking cessation in an ever daily smoker as not having smoked for 1 year, there was no significant

association between a lack of smoking cessation and schizophrenia after controlling for confounders, (OR = 1.2; CI 0.68–2.1) (de Leon et al. 2007a).

Is schizophrenia associated with more smoking in smokers?

An old review (Lohr and Flynn 1992) described clinicians' experience that schizophrenia smokers appear to smoke more cigarettes and be more addicted than other smokers. Since then, this statement has been continuously repeated in the literature. This section focuses on the design of studies testing the hypothesis that schizophrenia is associated with more smoking in smokers. Four types of studies are possible, focusing on (1) the increase in heavy smoking in schizophrenia smokers with respect to smokers from the general population; (2) the increase in heavy smoking in schizophrenia smokers with respect to smokers with other SMIs; (3) the high levels of nicotine dependence in schizophrenia smokers compared with smokers from the general population; or (4) the high levels of nicotine dependence in schizophrenia smokers compared with smokers with other SMIs. A somewhat connected hypothesis that is reviewed in the fifth subsection is whether heavy smoking in schizophrenia is associated with poorer prognosis in schizophrenia or not.

Is schizophrenia associated with increased heavy smoking within smokers when compared with the general population?

Published studies have used different definitions of heavy smoking, making it impossible to provide an average OR. However, they tend to suggest that schizophrenia smokers consistently smoke more than the smokers in the general population. In our meta-analysis, the male ORs ranged from 2.0 to 7.4, and the female ORs from 2.0 to 8.8 (de Leon and Diaz 2005). A US study controlling for gender, education, race, and age (OR = 2.9; CI 1.5, 5.6; Diaz et al. 2008) indicated that heavy smoking was significantly more frequent in schizophrenia smokers (42%) than in smokers without psychiatric disorders (14%).

Only a few studies have used biological methods to establish the possibility that schizophrenia smokers may have higher nicotine metabolite levels than other smokers without psychiatric disorders (Olincy et al. 1997; Strand and Nybäck 2005; Weinberger et al. 2007; Williams et al. 2005, 2010). It may be hard to definitively establish this fact, unless large studies of representative samples of smokers with schizophrenia and smokers without psychiatric disorders are completed and confounders are controlled. Not surprisingly, a urine level study did not find differences after controlling for the number of cigarettes smoked since they were controlling for smoking intensity (Bozikas et al. 2005).

Is schizophrenia associated with increased heavy smoking within smokers when compared with other SMIs?

The use of different heavy smoking definitions has made it impossible to provide an average OR when comparing heavy smoking in schizophrenia smokers versus smokers with other SMIs. The differences tend to be small and non-significant, with approximately 2/3 of ORs > 1 and 1/3 of them < 1. In our more recent US study the prevalence of heavy smoking within smokers was slightly higher in schizophrenia than in mood disorders (42 vs. 33%), but the difference was not significant after controlling for confounders (OR = 1.6; CI 0.94, 2.6; Diaz et al. 2008). There are no studies using biological measures comparing smokers with schizophrenia versus smokers with other SMIs.

Is schizophrenia associated with higher levels of nicotine dependence within smokers when compared with the general population?

Studies controlling for confounders and using measures of nicotine dependence based on the FTND (Gurpegui et al. 2005; Diaz et al. 2008) indicate that schizophrenia patients who

smoke are probably more dependent than smokers without psychiatric disorders. More interesting are three small studies (Tidey et al. 2005; Lo et al. 2011; Williams et al. 2011) reporting that when schizophrenia patients who smoke are matched to other highly dependent smokers, the former crave nicotine more; this is something that has been suspected for years (McKee et al. 2009; Weinberger et al. 2007).

Is schizophrenia associated with higher levels of nicotine dependence within smokers when compared with other SMIs?

We currently have good information from several countries showing that SMIs in general are consistently associated with higher levels of nicotine dependence than smokers from the general population (de Leon et al. 2002c, 2003; Diaz et al. 2009), but there is no definitive data showing that schizophrenia smokers smoke more or are more dependent than smokers with other SMIs. The small observed differences and the inconsistency of the results indicate that very large samples may be needed to settle this question.

In Western countries, heavy smoking and high nicotine dependence are also frequent in alcoholics and drug abusers. In a study of a treatment program for quitting smoking, alcoholism and schizophrenia were associated with poor outcomes (Gershon Grand et al. 2007). The only published comparison that we have found of nicotine dependence in smokers with schizophrenia versus smokers treated for alcohol and/or drug addictions is a Canadian study in an inpatient unit (Solty et al. 2009). The study included 84 psychotic patients (only 73%, 62/84, with schizophrenia or schizoaffective disorder) and 31 with primary diagnosis of addiction. The prevalences (uncorrected for gender) of current smoking were 55 and 77%, and of high dependence (FTND ≥ 6) were 47 and 65%, respectively (Solty et al. 2009).

Is smoking associated with worse prognosis within schizophrenia patients?

Another way of exploring the relationship between schizophrenia and heavy smoking is to compare the psychiatric outcome of schizophrenia patients who are heavy smokers with that of schizophrenia patients who are not, controlling for other factors that may influence prognosis. Many of the studies that provided high percentages of smoking in schizophrenia, 80–90%, were completed in long-term hospitals. This suggests that institutionalized patients, who usually have the worst prognoses, were more prone to smoke (de Leon and Diaz 2005). The few limited studies that have systematically explored the association between smoking and schizophrenia outcome indicate that smokers (compared to non-smokers) or heavy smokers (compared with mild smokers and non-smokers) tend to have poorer longitudinal prognoses (Aguilar et al. 2005; Salokangas et al. 2006; Kobayashi et al. 2010; Wang et al. 2010; Segarra et al. 2011). Please be aware that these results go directly against the idea of self-medication. If smoking is helpful, heavy smokers should have better prognosis than mild smokers or non-smokers. Many more studies controlling for confounding variables are needed to establish an association between smoking or heavy smoking in smokers and worse prognosis. If this fact is established by new studies, it may make sense to consider the hypothesis of allostasis. Kolb and Le Moal (1997) proposed that the organism tries to counteract the effects of a given drug through a vicious cycle in which the point where pleasure is achieved continuously changes in response to the administration of that drug. They argue that drug addiction results from dys-regulation of reward mechanisms and subsequent allostasis (chronic perturbation of brain reward homeostasis, in which stability can only be reached through change). Following the concept of allostasis, heavy smoking in schizophrenia may be a no-win situation associated with a major disturbance of the brain's compensatory systems, which are unable to adjust themselves despite patients' attempts to smoke heavily in order to adjust them (de Leon et al. 2005).

A proposed approach to studying the association between schizophrenia and smoking

This section begins with a summary of the complex information from epidemiological studies described in the two prior sections; it is followed by subsections on the implications of using SMI or non-psychiatric controls in these studies, and on our proposed study approach. Based on the above epidemiological information, we propose an approach to studying the association between schizophrenia and ever daily smoking. The main idea is to compare schizophrenia patients with non-psychiatric and bipolar controls by using a complex set of hierarchical hypotheses that will allow us to select consistently associated genes.

Summary of the epidemiological literature with a focus on planning genetic studies

Table 2 briefly summarizes the data supporting an association between schizophrenia and the various definitions of smoking behavior. In spite of the fact that there are more than 1,000 articles on the subject, the only association that appears to be definitively established is that of an increase in current smoking when compared with the general population. Unfortunately, many of the published studies do not provide data that allow investigating other definitions of smoking behavior. In particular, few studies report ever daily smoking rates. The limited available data suggest that for genetic studies, the best hypothesis is that schizophrenia is associated with an increase in ever daily smoking (Table 2).

Schizophrenia is a complex trait that results from genetic and environmental etiologic influences. As a matter of fact, it is unrealistic to consider it an etiologically homogenous entity (Kendler and Schaffner 2011). A meta-analysis of the twin literature indicates that schizophrenia heritability is 85% (73–90%) (Sullivan et al. 2003). The recent schizophrenia GWAS studies support a combination of rare and common genetic variations, a major role for polygenic inheritance, and a genetic overlap of schizophrenia and other psychiatric disorders such as bipolar disorder (Gejman et al. 2011). As smoking does not cause schizophrenia and the association of ever daily smoking with schizophrenia appears to indicate a shared vulnerability, this association can be used to explore a set of genes that may be associated with both schizophrenia and nicotine addiction.

Selecting SMI controls versus non-psychiatric controls

Non-psychiatric controls are likely to have much lower rates of ever daily smoking than schizophrenia patients. According to our meta-analysis of the few studies comparing schizophrenia with the general population in Western countries, the meta-analysis overall ORs are high: 7.3 for males, and 2.8 for females (Table 1). These large effect sizes suggest that future studies performing this comparison will have high statistical power.

The smaller difference between schizophrenia and SMIs will provide much lower statistical power but the authors believe that using controls with SMIs helps to eliminate some of the non-genetic confounders that may contribute to the association. People with SMIs and schizophrenia have been exposed to similar environments and treatments and are not likely to show differences in educational or socioeconomic status. Thus, according to our meta-analysis from a few studies comparing schizophrenia with other SMIs in Western countries, the ORs we expect to find will be lower than those comparing schizophrenia with the general population; the meta-analysis overall male OR was 2.0 and the female OR from two studies was non-significant (Table 1).

Therefore, SMI patients may be better controls than non-psychiatric subjects, but their inclusion in a study as controls will probably be accompanied by a reduction in statistical

power. SMI patients used as controls may bring an additional set of problems since they may have the genetic abnormalities associated with SMIs in general or with a specific SMI. If one believes that including all severe mood disorders together in a genetic study is not a good idea, and that major depressive disorder and bipolar disorder have very different genetic underpinnings, one can use only one of these two SMIs as a control group. Tables 3 and 4 provide a new review of the literature that allowed estimating the differences in ever smoking between schizophrenia and bipolar disorder, OR = 1.6 (1.1–2.2) (Table 3), and between schizophrenia and major depressive disorder, OR = 1.8 (1.2–2.7) (Table 4). These meta-analysis overall ORs were calculated using two types of studies: some were using research diagnoses and others clinical diagnoses. Obviously a good comprehensive genetic study may benefit from the use of the more accurate research diagnoses rather than clinical diagnoses. But it is also important to keep in mind that the studies that were used to estimate the differences between schizophrenia and mood disorders (Diaz et al. 2009) and ORs and PARs (de Leon et al. 2005) as described in Table 5 used the less accurate clinical diagnoses.

We believe that bipolar disorder is a more reasonable choice as a control in schizophrenia studies than major depressive disorder since it is a more homogenous concept, and is frequently associated with psychosis and chronic antipsychotic treatment. Unfortunately, the limited data from four published studies indicate that increased ever smoking in schizophrenia compared with bipolar disorder is probably small, with an average OR = 1.6 (Table 3), which would require hundreds of patients to prove a significant difference in a genetic factor.

Major depressive disorder appears to be a less reasonable choice because it is a less homogenous concept than bipolar disorder, and is rarely associated with psychosis or chronic antipsychotic treatment. On the positive side, the prevalence of major depressive disorder in the general population is much higher than that of bipolar disorder, and the former disorder may have a slightly weaker association with smoking than the latter. Thus, if this weaker association is true, a study using patients with major depressive disorder may have more statistical power than a study of comparable sample size with bipolar patients. In the majority of cases, nicotine addiction begins before depression develops (Rohde et al. 2003, 2004). In a US female twin study, Kendler et al. (1993) found that ever daily smoking and lifetime major depression share some vulnerability, which is probably explained by genetic factors. In a Swedish twin study, Edwards et al. (2011) found a similar shared genetic vulnerability in males, and shared genetic and unique environmental influences in females. Since in epidemiological studies the association between major depressive disorder and nicotine addiction is weaker than that between schizophrenia and nicotine addiction, we suspect that major depressive disorder shares a smaller amount of genetic variability with nicotine addiction than does schizophrenia. Moreover, in our sample of US patients with SMIs, neither major depressive disorder nor bipolar disorder were associated with ever daily smoking within patients with SMIs after correcting for other addictions (de Leon et al. 2005). However, the association between schizophrenia and ever daily smoking was significant after controlling for addictions. Thus, it is possible that the association between severe mood disorders (bipolar and major depressive disorders) and nicotine addiction may merely reflect that (1) severe mood disorders are also associated with other addictions, and (2) other addictions are associated with ever daily smoking. Thus, the associations between severe mood disorders and ever daily smoking may not survive the control for other addictions (Black et al. 1999; Rohde et al. 2003, 2004) and high smoking rates in severe mood disorders may be mainly explained by comorbid addictions (Lawrence et al. 2009).

Another factor confounding the association between depression and smoking is suggested by the self-medication hypothesis. Although we do not believe that the self-medication hypothesis satisfactorily explains the association between schizophrenia and tobacco

addiction, there is some evidence suggesting that it may explain the difficulties with smoking cessation that depressed patients have. In non-smokers nicotine appears to be an antidepressant (Salin-Pascual et al. 1996). Tobacco smoke inhibits monoamine oxidase (MAO) activity through epigenetic mechanisms. Drugs that are MAO inhibitors are antidepressants, so it is possible that smoking may have some antidepressant effects through this inhibition (Rendu et al. 2011). Some vulnerable patients with a history of recurrent depression may become depressed when they stop smoking (Covey et al. 1998), but not all studies agree with this hypothesis (Hitsman et al. 2003). More recently, one of the large US epidemiological surveys suggested that patients with mood disorders are more prone to experience tobacco withdrawal symptoms and distress (Weinberger et al. 2010); a clinical trial suggested that patients with history of depression have lower expectations of quitting (Weinberger et al. 2011), and, according to an epidemiological study, there are complex interactions between depression and obesity in female ever smokers (Widome et al. 2009). Twin studies indicate that psychiatric disorders, including major depressive disorder, may worsen nicotine withdrawal, which may contribute to lower smoking cessation rates (Xian et al. 2005; Edwards and Kendler 2011).

A study approach to searching for genes that explain the increased ever daily smoking seen in schizophrenia

Ever daily smoking may be associated with hundreds of thousands of genes of modest effects, but we are interested in those shared with schizophrenia. Exploring the association of schizophrenia with ever daily smoking using GWAS with millions of genetic variations may provide many false positives. To reduce the false positives due to chance, we propose to follow a study approach that uses a set of hypotheses developed after reviewing epidemiological data. This study approach can be used in an exploratory GWAS with millions of genetic variations or in a more focused candidate gene approach using thousands of genes selected a priori. Thus, the design (GWAS versus candidate gene study) will determine the number of genetic variations tested and the sample size. The recruited sample for any study testing the first-stage hypotheses can easily be used to test the second- and third-stage hypotheses.

To best explore the genetics of the association between ever daily smoking and schizophrenia, one can use simultaneously non-psychiatric controls and controls with other SMIs to take advantage of the progressive increase in ever daily smoking prevalence seen from non-psychiatric controls to schizophrenia, with other SMIs (e.g., bipolar disorder) having intermediate prevalences. The essence of our approach is that if an individual genetic variation is truly involved in the association between schizophrenia and smoking, then we expect that this variation rejects simultaneously a set of carefully selected null hypotheses that should be false according to epidemiological studies. Since the chance is very small that all hypotheses are rejected simultaneously with a genetic variation that is not truly involved in the association, the type I error of a study following our approach will be small and, therefore, the chance of obtaining many false positives is substantially reduced. For illustration purposes, it is assumed that a nominal (uncorrected) significance level of $\alpha = 0.01$ is used to test each null hypothesis described below. This level is selected according to the preference of the investigators.

In the first stage of our approach (Fig. 1), only genetic variations associated with ever daily smoking versus non-ever daily smoking will be selected that are significant at the nominal level simultaneously within the non-psychiatric controls, the bipolar disorder controls, and the schizophrenia cases. That is, for a particular genetic variation, three null hypotheses of no association between the genetic variation and ever daily smoking are tested, one for each of the three subject groups. Provided that confounders such as gender or socioeconomic status are controlled for in the test procedure, if the genetic variation is not involved in ever

daily smoking, the probability that the three null hypotheses are rejected simultaneously will be at most $\alpha^3 = 10^{-6}$.

In the second stage of our approach (Fig. 1), only those genetic variations that were significant in each of the tests of the three above null hypotheses will be examined. The prevalence of these variations increasing the risk of smoking in schizophrenia would have to be significantly higher in schizophrenia than in bipolar disorder and, simultaneously, significantly higher in bipolar disorder than in controls. If a genetic variation is not involved in the association between schizophrenia and ever daily smoking, the possibility that it is selected in both the first and second stage, that is, the possibility that it simultaneously produces five significant tests is at most $\alpha^5 = 10^{-10}$, provided confounders have been controlled for. The reason is that, for an irrelevant genetic variation, we do not expect that a non-significant result in the comparison of schizophrenia patients with bipolar patients changes our nominal probability of type I error in the comparison of bipolar patients with non-psychiatric controls.

The positively associated gene variations that were selected in both the first and second stages will be entered into a third stage (Fig. 1). According to epidemiological findings, each of these gene variations will need to have a significantly higher prevalence in people with schizophrenia who started daily smoking after the age of 20 than in people with schizophrenia who had an early start (20 years or younger). According to our more recent US study with 235 schizophrenia patients (de Leon et al. 2006; Diaz et al. 2008), we estimate that 16.6% will be never daily smokers, 58.3% ever daily smokers with early onset of daily smoking (<20 years of age) and 25.1% ever daily smokers with late onset of daily smoking (≥ 20 years of age). If appropriate confounders are controlled for, the possibility that an irrelevant genetic variation is selected simultaneously in all three stages will therefore be, at most, 10^{-12} .

The prior description refers to genetic variations associated with increased risk. Protective gene variations will have opposite patterns: (1) in the first stage, significantly lower gene-variation prevalences in ever daily smokers than in non-ever daily smokers will be simultaneously observed within the non-psychiatric controls, the bipolar disorder controls and the schizophrenia cases; (2) in the second stage, a significantly lower prevalence in schizophrenia than in bipolar disorder and, simultaneously, a significantly lower prevalence in bipolar disorder than in non-psychiatric controls will be observed; and (3) in the third stage, a significantly lower prevalence will be observed in people with schizophrenia who started daily smoking after the age of 20 in comparison with people with schizophrenia who had an early start (20 years or younger).

Thus, although the nominal significance level for testing each individual hypothesis is 0.01, the nominal significance level for our 3-stage approach with 6 hypotheses will be much smaller, 10^{-12} . Since many genetic variations will be examined, correction of p values for multiple comparisons at each individual hypothesis testing can be performed if desired. Our approach, however, will still reduce the final probability of type I error in this case by raising the corrected significance level to a power of about 6 and will also produce a set of candidate genes that are meaningful from an epidemiological point of view, not just from a statistical-significance perspective.

Association between nicotine and alcohol addictions

The aim of our study approach was to build a genetic psychiatric explanation of the comorbidity of schizophrenia and nicotine addiction. To fully understand our approach, it is necessary to pay attention to other psychiatric comorbidities, particularly alcohol and drug

addictions. This section focuses on the association between nicotine and alcohol addictions and the next one between nicotine and drug addictions.

Alcohol is widely used in many countries, although it is used in smaller proportions in the Middle East, Africa and China (Anderson 2006; Degenhardt et al. 2008). According to the National Epidemiology Survey on Alcohol and Related Conditions (NESARC) study in the US, the prevalence of alcohol addiction during the 12 months prior to the study was 8.5% (12.4% in men and 4.5% in women; Grant et al. 2004).

The following issues are reviewed below in subsections: (1) the genetics of nicotine and alcohol addiction, (2) the association between tobacco and alcohol use in the general population, (3) the association between nicotine and alcohol addictions in clinical samples, and (4) the association between schizophrenia and alcohol addiction.

Genetics of tobacco and alcohol use or addiction

Tobacco and alcohol use and their addictions are associated in the general population of Western countries. The use of alcohol and tobacco may be related in two ways: (1) intrapersonal linkage (alcohol drinkers usually smoke and vice versa) and (2) situational linkage (people who use alcohol and tobacco may use them together in the same situations) (Schiffman and Balabanis 1995). To explain these links genetic, coping, pharmacological, learning, personality, and cultural factors have been proposed (Niaura and Shiffman 1995; Bien and Burge 1990; Room 2004). The intrapersonal linkage has interest for geneticists. Any intrapersonal linkage has the potential of being explained by genetic factors. There is good information on the genetics of alcohol addiction but there is less understanding on the genetics of alcohol use. Two facts are important: (1) polymorphisms that decrease alcohol metabolism have major effects on alcohol use and therefore are protective for alcohol addiction (they are frequent in Asian populations but rare in European and African populations) (Bierut 2011), and (2) US twin studies indicate that familial and social factors are important determinants of alcohol use (Kendler et al. 2011). This is in contrast with alcohol addiction, where genetic and temperamental factors are more critical (Kendler et al. 2011).

The estimates of the heritability of alcohol addiction are 51–65% in females and 48–73% in males (Tyndale 2003). It has been suggested that genetic influences explain a substantial portion of the covariance of nicotine and alcohol addictions (Swan et al. 1990, 1997; Lessov-Schlaggar et al. 2006). In contrast with GWAS studies of nicotine addiction, GWAS studies of alcohol addiction have not yet provided robust findings (Bierut 2011).

Association between tobacco smoking and alcohol use in the general population

In the US, epidemiological studies have demonstrated that tobacco and alcohol addictions are associated to the point that smoking status can be used as a possible marker of alcohol addiction (McKee et al. 2007) and that the severity of tobacco addiction increases with the severity of alcohol addiction (Falk et al. 2006). In the National Comorbidity Survey (NCS) study (Lasser et al. 2000), alcohol addiction was present in 22% of the general population versus 66% of ever smokers and was significantly associated with ever smoking. However, the analysis did not control for other psychiatric disorders. As far as we know, there are no meta-analyses of the association between alcohol and tobacco use that summarize the epidemiological studies throughout the world and provide an idea of this association's variability.

Alcohol use varies widely in non-Western countries probably due to cultural and biological differences. Thus, shared genetic vulnerability between alcohol and nicotine use should vary widely across the world. The next two paragraphs summarizing epidemiological studies (de

Leon et al. 2005) provide support to the finding from twin studies, that non-genetic factors may be crucial for understanding alcohol use and, therefore, its interaction with nicotine use in the general population.

When using epidemiological studies on alcohol and nicotine use as a guide for genetic studies, three key issues must be considered: (1) different definitions of alcohol and nicotine use (current, ever users, or quitters) may provide different results; (2) lifetime regular alcohol use (persistence of drug use) may be the best target according to what we know from addiction genetics; and (3) any epidemiological association that is not stable over time or not replicated in various countries is not likely to be explained by genetics. We explored the nicotine-alcohol association in the general population of two Western countries, the US and Spain (Basque country area), over a short period of time, 1992–1996 (de Leon et al. 2007b). Some of the observed associations were stable across the two general populations and subsamples determined by gender and race, but others were not. Table 5 describes the strength and relevance of the association between ever smoking and lifetime alcohol use by providing adjusted ORs and PARs.

In our study of two countries (de Leon et al. 2007b), the strength of the association between ever smoking and lifetime alcohol use, measured by ORs, was significantly higher in the US general population than in the Basque region of Spain (Table 5). Also, there were higher PARs for the US than for the Basque country (about 80–90% vs. about 60%, respectively; Table 5). Thus, in both countries tobacco smoking and alcohol use were strongly associated with each other, but the association was significantly stronger in the US. This comparison provides an idea of the complexity of trying to explore the association of ever smoking and lifetime alcohol use in the general population. We believe that this association may be strongly influenced by cultural differences and that alcohol use in the general population may be influenced by non-biological factors, too. In the Basque country, weekly drinking is a socially approved behavior. Therefore, in 1992 and 1996, alcohol drinking was much more frequent in the Basque region of Spain than in the US (45–47 vs. 22–24%, respectively). Consequently, since many people drink socially in the Basque country, those with a vulnerability to alcohol use disorders are a minority and social drinkers are a majority. In the US, where social drinking is less acceptable and there was more social pressure for smoking cessation, the strong relation between ever smoking and ever drinking was probably influenced by a higher percentage of people with higher biological vulnerability and more risk of becoming addicted (de Leon et al. 2007b). Therefore, in an interpretation that is consistent with the results from twin studies, the association between nicotine and alcohol use is substantially affected by cultural factors that are important in influencing alcohol use.

Association between nicotine and alcohol addictions in clinical samples

Smoking is very frequent in clinical samples of alcohol addicts but there are no meta-analyses or comprehensive reviews of the studies. This is not surprising since researchers investigating an addiction tend to ignore addictions other than the one in their field of research (Kozłowski et al. 1990). Published current smoking prevalences are >80% for alcohol addicts (Hughes 1996) and >75% for alcohol addicts in early recovery (Kalman et al. 2005).

Association between schizophrenia and alcohol addiction

Schizophrenia review articles have provided ranges of alcohol addiction prevalence of 25–45% (Buckley 2006) or 21–86% (Volkow 2009). More recently, Koskinen et al. (2009) completed a meta-analysis of studies from mainly Western countries that indicated that approximately one-fifth of schizophrenia patients had a diagnosis of lifetime alcohol addiction but there was a very high variability in study prevalences, a decreasing trend over

years and a lack of control for smoking effects. A more recent Swedish schizophrenia study with a large cohort indicated a prevalence of alcohol addiction of 8%, higher than in the Swedish general population (Jones et al. 2011) but lower than in US schizophrenia studies.

Association between nicotine and drug addictions

Drugs other than alcohol and nicotine are frequently used and abused all over the world. Cannabis is used all across the world. Opiate use is concentrated in Asia and Europe, and cocaine use is concentrated in the Americas and to a lesser extent in Europe (Anderson 2006; Degenhardt et al. 2008). According to the NESARC study, the US prevalence of any reported drug addiction during the 12 months prior to the study was 2.0% (2.8% in men and 1.2% in women) (Grant et al. 2004).

The following issues are reviewed in the following subsections: (1) the genetics of nicotine and drug addictions; (2) the association between tobacco and drug use in the general population; (3) the association between nicotine and drug addictions in clinical samples; and (4) the association between schizophrenia and drug addiction.

Genetics of tobacco and drug use or addiction

Tobacco and other drug use and their addictions are associated in Western countries. Most of the studies focused on the association between drugs and tobacco tend to include all drugs together rather than separate specific drugs. Twin studies support the following: (1) initiation and early patterns of drug use are strongly influenced by social and familial environmental factors whereas later levels of use are strongly influenced by genetic factors (Kendler et al. 2008), (2) there are common genetic influences shared by all drugs (Xian et al. 2008; Vanyukov et al. 2009), and (3) there are unique environmental and genetic influences for specific drugs (Kendler et al. 2007; Xian et al. 2008). Kendler et al. (2005) commented that measures of availability may be important but difficult to establish for illegal drugs; thus, using drug use as a measure of availability may be practical but far from ideal. Agrawal et al. (2010) focused on the association between nicotine and cannabis addictions in a twin study, indicating that complex bidirectional models are possible (e.g., cannabis influences tobacco, and tobacco influences cannabis addiction).

As drug addictions are less frequent than nicotine and alcohol addictions, there have not been large-scale GWAS investigating drug addiction; the genetic approach has mainly focused on candidate gene studies. However, there have been few replications (Bierut 2011).

Association between tobacco smoking and drug use in the general population

In Western countries, tobacco use and drug use are associated in the general population. Large epidemiological studies have demonstrated that tobacco and drug addictions are associated in the US. In the 1997 National Household Survey on Drug Abuse, Richter et al. (2002) found that 71% of recent illicit drug users smoked cigarettes at least once in the past month. The adjusted smoking OR was 3.1 when comparing drug users versus the general population. Polyversus mono-drug users have higher prevalences of being a smoker (OR = 2.4). In the NCS study, Lasser et al. (2000) described drug addiction as present in 11% of the general population versus 72% of ever smokers, and was significantly associated with ever smoking; however, they did not control for other psychiatric disorders. In the same study, Breslau et al. (2004a, b) found that (1) current smoking was associated with current alcohol and drug addiction after controlling for one or the other but past smoking was not associated with them, and (2) current but not past smoking predicted subsequent onset of alcohol and drug addiction. This suggests that there may not be a shared vulnerability between ever smoking and other addictions and that it is current smoking that contributes to other addictions. In an Australian epidemiological study, Degenhardt and Hall (2001a)

demonstrated that the association between smoking and current drug addictions persisted after controlling for alcohol addiction. Moreover, smoking, alcohol, and cannabis addictions appear to have independent effects on other addictions (Degenhardt et al. 2001). A recent worldwide study indicated that it is important to accurately estimate the stability of the interactions between alcohol and tobacco use, since it appears that the initiation of alcohol and tobacco use interacts with the prevalence of alcohol and tobacco use to increase the subsequent onset of illicit drugs (Degenhardt et al. 2010). The effect of nicotine and alcohol use to subsequently potentiate illegal drug use has been called the gateway theory (Wagner and Anthony 2002).

Association between nicotine and drug addictions in clinical samples

Smoking is very frequent in clinical samples of drug addicts under treatment but there are no meta-analyses or comprehensive reviews of studies. Review articles provide estimations of current smoking prevalences >80% in drug addicts (Hughes 1996), >75% in drug addicts in early recovery, and 80% in cocaine and opioid addicts (Kalman et al. 2005). Some large US clinical studies reported current smoking prevalences of 75% (Budney et al. 1993) and 83% (Pattkar et al. 2006). After reviewing studies in the US and the UK, Richter and Arnsten (2006) reported prevalences of 77–93%.

Association between schizophrenia and drug addiction

We have not found meta-analyses of the association between schizophrenia and addictions to drugs in general. We have found only a meta-analysis for one specific drug, cannabis (Koskinen et al. 2010). Cannabis use is particularly important because there is considerable information suggesting that the secondary schizophrenia model may be partly true; cannabis may explain some cases of schizophrenia (Van Os et al. 2010), but probably not more than 5–7% (Buckley et al. 2009).

In the 1980s, the ECA indicated that patients with schizophrenia had a lifetime history of drug addiction of 47% (Regier et al. 1990). In a large sample of US schizophrenia patients recruited by a National Institute of Health (NIH) study in the 2000s, 60% of schizophrenic patients were using substances (nicotine was not included) and 37% met criteria for alcohol or drug addiction (Swartz et al. 2006). Westermeyer (2006) has proposed that the prevalence of lifetime addiction may have increased up to 70–80% in US schizophrenia patients.

Controlling for other comorbidities in our approach

After reading the prior two sections on the interactions between nicotine addiction and alcohol/drug addictions and between schizophrenia and alcohol/drug addiction, a legitimate question is: how much of the association between schizophrenia and nicotine addiction is left after eliminating the effects of alcohol or drug addiction? Can the association between schizophrenia and nicotine addiction merely reflect the association between schizophrenia and other drug addictions?

In this section, we use two pieces of information to answer this question: (1) the review of epidemiological studies and (2) one of our studies that provided adjusted ORs and PARs to measure the association between schizophrenia and ever daily smoking. Then, a subsection puts this association in context with other psychiatric comorbidities described in this article; and a final subsection explains how these comorbidities can be introduced in the model.

Schizophrenia and ever daily smoking after controlling for other addictions in worldwide epidemiological studies

We believe that our review of worldwide epidemiological studies (de Leon and Diaz 2005) suggests that it is not likely that the association between schizophrenia and nicotine addiction can be completely explained by other addictions. The association of schizophrenia with smoking is more consistent and stronger than the association of schizophrenia with other addictions and is more likely to be explained by a shared vulnerability model between schizophrenia and nicotine addiction.

Regarding consistency, the association between schizophrenia and nicotine addiction appears to be more consistent around the world and has been demonstrated in non-Western countries. There is no data on the association between schizophrenia and alcohol/drug addiction in non-Western countries.

Regarding strength, the association between schizophrenia and current nicotine addiction appears to be stronger, with a world average prevalence of nicotine addiction of 60% (de Leon and Diaz 2005). The association between schizophrenia and current alcohol addiction appears to be weaker, with an average prevalence of one-fifth in Western countries (Koskinen et al. 2009). The schizophrenia worldwide average is probably lower for current drug addictions but has not been studied.

There are no large epidemiological studies in the general population studying the association between schizophrenia and nicotine addiction after controlling for other addictions. However, in an Australian survey, Degenhardt and Hall (2001b) studied psychotic symptoms by self-report without determining how many of the psychotic individuals had schizophrenia and/or drug-induced psychosis. It was not surprising that alcohol and cannabis addictions and severe cases of opioid addictions were independently associated with psychotic symptoms; all of them can cause secondary psychosis during chronic use and/or withdrawal. Interestingly, daily smoking was also independently associated with psychosis. As tobacco does not cause psychotic symptoms, it is possible that this association found in the Australian general population may be explained by the association between schizophrenia and daily smoking.

Schizophrenia and ever daily smoking after controlling for other addictions in an SMI study

As far as we know, only one study in patients with SMIs has tried to control for the effects of other addictions when examining the association between schizophrenia and nicotine addictions (de Leon et al. 2005). Moreover, this study can be used to establish the effect sizes and relative importance of the various addictions in SMIs.

First, it is important to state that severe mood disorders, bipolar and major depressive disorder, separate or together, were not associated with ever daily smoking in this sample of SMIs since they were much less strongly associated with nicotine addiction than schizophrenia. We can conclude that it would not be surprising that much of the association between mood disorders and nicotine addiction may merely reflect the high levels of alcohol and drug addiction in patients with severe mood disorders.

Second, the association between schizophrenia and nicotine addiction was stronger and survived the control for alcohol and drug addictions. The adjusted OR measuring the association between ever smoking and lifetime alcohol was 3.6, and that measuring the association between ever smoking and drug use was 3.0; these numbers were somewhat higher than the OR measuring the association between ever smoking and schizophrenia 2.0 (Table 5). Although these ORs were not significantly different, they suggest that in an

average patient with SMI it is possible that lifetime alcohol and drug addictions are better predictors of ever daily smoking than schizophrenia. What is remarkable is that this study indicates that there was still an ever daily smoking PAR of 21% that reflected schizophrenia effects even after correcting for other addictions. This fact indicates to us that there is hope for a gene study on the association between schizophrenia and ever daily smoking.

Our approach in the context of other comorbidities

Schizophrenia is probably a heterogeneous disorder that is influenced by genes and environment with a 73–90% heritability (Sullivan et al. 2003) and is probably the result of a combination of rare and common genetic variants (Gejman et al. 2011). Schizotypy, which is frequent in schizophrenia relatives, may be a manifestation of the same genetic vulnerability (Nuechterlein et al. 2002; Fanous et al. 2007). Interestingly, schizotypy may also be associated with increased current smoking (Esterberg et al. 2007; Stewart et al. 2010).

The smoking persistence heritability is 46% in females and 59% in males (Li et al. 2004) and may be explained by thousands of genes with moderate effects (Bierut 2011). Some of these genes associated with nicotine addiction may contribute to the increased ever daily smoking seen in schizophrenia. Our study approach to the association between schizophrenia and smoking can help to select significant genetic variants by using a strategy developed by our knowledge of epidemiology.

In a group of patients with SMIs, the genes associated with ever daily smoking may include some that are specific to nicotine addiction (e.g., pharmacokinetic genes) and some that are shared with lifetime alcohol addiction, lifetime drug addiction, and schizophrenia. Table 5 indicates that each of these three shared disorders may have an independent effect after controlling for the other two and, more importantly, a relevant association between schizophrenia and ever daily smoking is left after controlling for lifetime drug addictions (OR = 2.0 and PAR = 21%). The epidemiological review of the literature suggests that shared genetic factors probably explain the association of schizophrenia with ever daily smoking. All arguments reviewed in this article that indicate the potential for genetic studies in this area can be summarized as follows: (1) smoking does not cause schizophrenia, (2) the consistency and strength of the association between schizophrenia and ever daily smoking around the world is consistent with the hypothesis of a shared genetic component, and (3) the persistence of this association after eliminating the effects of other drug addictions suggests that this association is specific and is likely to reflect a set of genes completely different from the ones expected from a shared vulnerability to all drugs of addiction. Our model has reasonable potential for providing gene variants associated with schizophrenia and ever daily smoking since: (1) the high frequency of ever daily smoking in schizophrenia patients in Western countries makes the phenotype frequent and easy to study; (2) the increased level of ever daily smoking comparing schizophrenia versus bipolar disorder and the genetic continuity between these disorders (Gejman et al. 2011) provides a model of continuous vulnerability that can be further improved by incorporating non-psychiatric controls to test for gene specificity; and (3) the peculiarity of schizophrenia patients who may get addicted to nicotine in their 20s contrasts with non-psychiatric controls who do not provide further help in selecting relevant gene variants. Table 6 compares the potential for genetic studies to examine the association between schizophrenia and ever daily smoking with the study of other comorbidities in psychiatry. Since psychiatric disorders are essentially comorbid disorders (Kendler et al. 2003), their comorbidity needs to be included in genetic studies. Table 6 briefly reviews three relevant types of comorbidities discussed in this article: (1) ever daily smoking with other lifetime drug addictions (upper panel); (2) severe mood disorders with ever daily smoking (middle panel); and (3) schizophrenia with other lifetime drug addictions (lower panel).

The association between ever daily smoking and lifetime alcohol addiction would be explained by a combination of genetic and environmental factors and their interactions. The genetic factor relative weight is unknown (Table 6 upper panel). Similarly, the association between ever daily smoking and lifetime drug addiction would also be explained by a combination of genetic factors, environmental factors, and their interactions. Unfortunately, the association between ever daily smoking and lifetime drug addiction should be quite difficult to study since (1) it may include a general component and other components specific to each drug, and (2) alcohol use is a confounding factor since it may serve as a gateway to addiction to other drugs.

The middle panel of Table 6 summarizes the lesser potential for genetic studies of the association between severe mood disorders and ever daily smoking when compared with the association between schizophrenia and ever daily smoking. The association is (1) less consistent and is difficult to detect in situations involving low smoking levels and floor effects (Campo-Arias et al. 2006); (2) weaker; and (3) perhaps explained by the association between severe mood disorders and other addictions.

The lower panel of Table 6 compares the potential of genetic studies of the association between schizophrenia and ever daily smoking with those between schizophrenia and other lifetime addictions. Studying the latter association is much more difficult since other lifetime addictions are less frequent and the association is less consistent throughout the world. Moreover, bidirectional relations would make the study of the association between schizophrenia and some illegal drugs such as cannabis very complex.

Controlling for other comorbidities in the model

Using bipolar patients as controls, who tend to abuse alcohol and drugs more frequently than schizophrenia patients (Regier et al. 1990), may help eliminate the genes shared by ever daily smoking and other lifetime addictions. Please be aware that the second stage of our study approach looks for genes that increase the risk of daily smoking when comparing schizophrenia with bipolar disorder. This should eliminate genes associated with other drug addictions (Table 6).

An additional way of eliminating significant genes in the first stage of our approach is to eliminate any gene that is significantly associated with alcohol and drug addictions in the psychiatric patients. That is, after combining the samples of schizophrenia and bipolar patients, genetic variants significantly higher in patients with addictions versus those without addictions can be eliminated.

Conclusions

The many articles on the association between schizophrenia and tobacco smoking are limited by a lack of attention to (1) differences between statistical associations and causal relationships, and (2) the consistency and replication of findings. This association can be studied by (1) focusing on current smoking, ever smoking or smoking cessation; (2) using non-psychiatric or SMI controls; and (3) testing an increase in smoking prevalence or an increase in smoking levels within smokers. An increase in current smoking is consistently observed in schizophrenia patients from many countries around the world when compared with the general population and may be demonstrated unless too few or too many smokers are present in the general population.

Both schizophrenia and nicotine addiction exhibit high levels of heritability. The definition of smoking behavior that has greater potential for genetic studies is ever daily smoking, since the association between ever daily smoking and schizophrenia probably reflects a

shared genetic vulnerability. Ever daily smoking may be associated with hundreds of thousands of genes of modest effects, but according to our epidemiological data it is likely that some of them are shared with schizophrenia and not shared with other addictions. Exploring the association of schizophrenia with ever daily smoking using a GWAS with millions of genetic variations or a candidate gene study with thousands of genetic variations may provide many false positives. To reduce the number of false positives due to chance, we propose to use a three-stage approach that uses six hypotheses developed after reviewing epidemiological data. In the first stage of our approach, only genetic variations associated with ever daily smoking versus non-ever daily smoking will be selected that are simultaneously significant within the non-psychiatric controls, within the bipolar disorder controls and within the schizophrenia cases. Only those genetic variations that are simultaneously significant in the three hypothesis tests of the first stage will be tested in the second stage. The prevalence of these genes increasing the risk of smoking in schizophrenia would have to be significantly higher in schizophrenia than in bipolar disorder, and significantly higher in bipolar disorder than in controls. The positively associated genes that are simultaneously significant in the two hypothesis tests of the second stage will be introduced in a third stage. These gene variations will need to be significantly more frequent in people with schizophrenia who started daily smoking in their 20s (21 years or older) than in those who had an early start (20 years or younger). Protective genes will have the inverse pattern of risk genes in the six hypotheses.

Epidemiological and genetic studies suggest that nicotine addiction overlaps with alcohol and drug addictions. Using bipolar patients as controls, who tend to abuse alcohol and drugs more frequently than schizophrenia patients, may help eliminate the genes shared by ever daily smoking and other lifetime addictions. An additional way of filtering out unwanted genes from the genes that were significant in the first stage is to eliminate any gene that is significantly associated with both alcohol and drug addictions.

Psychiatric disorders are highly comorbid disorders. There is great comorbidity between SMIs and addictions and between the various addiction types. Our study approach may be of interest for researchers in psychiatric genetics, even if they are not particularly interested in the association between schizophrenia and smoking. We believe that any genetic approach to psychiatric disorders may fail if comorbidity is not taken into account and careful attention is not paid to the epidemiological studies that suggest which comorbidities are likely to be explained by genetics and which are not. Finally, we speculate that our approach which examines the results of epidemiological studies on comorbidities and then looks for genes that simultaneously satisfy epidemiologically suggested sets of hypotheses, may also apply to the study of other major illnesses, such as cancer, diabetes, or autoimmune diseases, in which a mosaic of non-secondary comorbidities is usually present.

Acknowledgments

F. Diaz, Ph.D. was partly supported by an NIH Institutional Clinical and Translational Science Award to the University of Kansas Medical Center (1ULRR033179, R033177, RR033178). No commercial organizations had any role in the writing of this paper for publication. The authors acknowledge Lorraine Maw, M.A., and Margaret T. Susce, R.N., M.L.T., at the Mental Health Research Center at Eastern State Hospital, Lexington, KY, who helped in editing the article and managing the large number of articles reviewed. The authors are grateful to the reviewers who helped them to clarify issues and improve the article.

References

- Agrawal A, Silberg JL, Lynskey MT, Maes HH, Eaves LJ. Mechanisms underlying the lifetime co-occurrence of tobacco and cannabis use in adolescent and young adult twins. *Drug Alcohol Depend.* 2010; 108:49–55. [PubMed: 20047801]

- Aguilar MC, Gurpegui M, Diaz FJ, de Leon J. Nicotine dependence and symptoms in schizophrenia: naturalistic study of complex interactions. *Br J Psychiatry*. 2005; 186:215–221. [PubMed: 15738502]
- American Psychiatric Association. Diagnostic and statistical manual: third edition DSM-III. American Psychiatric Press; Washington DC: 1980.
- Anderson P. Global use of alcohol, drugs and tobacco. *Drug Alcohol Rev*. 2006; 25:489–502. [PubMed: 17132569]
- Bien TH, Burge R. Smoking and drinking: a review of the literature. *Int J Addict*. 1990; 25:1429–1454. [PubMed: 2094682]
- Bierut LJ. Genetic vulnerability and susceptibility to substance dependence. *Neuron*. 2011; 69:618–627. [PubMed: 21338875]
- Black DW, Zimmerman M, Coryell WH. Cigarette smoking and psychiatric disorder in a community sample. *Ann Clin Psychiatry*. 1999; 11:129–136. [PubMed: 10482122]
- Bolton JM, Robinson J. Population-attributable fractions of axis I and axis II mental disorders for suicide attempts: Findings from a representative sample of the adult, noninstitutionalized US population. *Am J Public Health*. 2010; 100:2473–2480. [PubMed: 21068419]
- Bozikas VP, Niopas I, Kafantari A, Kanaze FI, Gabrieli C, Melissidis P, Gamvroula K, Fokas K, Karavatos A. No increased levels of the nicotine metabolite cotinine in smokers with schizophrenia. *Prog Neuropsychopharmacol Biol Psychiatry*. 2005; 29:1–6. [PubMed: 15610938]
- Breslau N, Novak SP, Kessler RC. Daily smoking and the subsequent onset of psychiatric disorders. *Psychol Med*. 2004a; 34:323–333. [PubMed: 14982138]
- Breslau N, Novak SP, Kessler RC. Psychiatric disorders and stages of smoking. *Biol Psychiatry*. 2004b; 55:69–76. [PubMed: 14706427]
- Buckley PF. Prevalence and consequences of the dual diagnosis of substance abuse and severe mental illness. *J Clin Psychiatry*. 2006; 67(suppl 7):5–9. [PubMed: 16961418]
- Buckley PF, Miller BJ, Lehrer DS, Castle DJ. Psychiatric comorbidities and schizophrenia. *Schizophr Bull*. 2009; 35:383–402. [PubMed: 19011234]
- Budney AJ, Higgins ST, Hughes JR, Bickel WK. Nicotine and caffeine use in cocaine-dependent individuals. *J Subst Abuse*. 1993; 5:117–130. [PubMed: 8400835]
- Campo A, Díaz LA, Rueda GE, Rueda M, Farelo D. Prevalencia de consumo de cigarrillo en pacientes de la consulta psiquiátrica de Bucaramanga. *Colombia Médica*. 2004; 35:69–74.
- Campo-Arias A, Díaz-Martínez LA, Rueda-Jaimes GE, Rueda-Sánchez M, Farelo-Palacín D, Diaz FJ, de Leon J. Smoking is associated with schizophrenia, but not with mood disorders, within a population with low smoking rates: a matched case-control study in Bucaramanga, Colombia. *Schizophr Res*. 2006; 83:269–276. [PubMed: 16497482]
- Chapman S, Ragg M, McGeechan K. Citation bias in reported smoking prevalence in people with schizophrenia. *Aust N Z J Psychiatry*. 2009; 43:277–282. [PubMed: 19221917]
- Covey LS, Hughes DC, Glassman AH, Blazer DG, George LK. Ever-smoking, quitting, and psychiatric disorders: evidence from the Durham, North Carolina, and epidemiological catchment area. *Tob Control*. 1994; 3:222–227.
- Covey LS, Glassman AH, Stetner F. Cigarette smoking and major depression. *J Addict Dis*. 1998; 17:35–46. [PubMed: 9549601]
- de Leon J. Smoking and vulnerability for schizophrenia. *Schizophr Bull*. 1996; 22:405–409. [PubMed: 8873291]
- de Leon J, Diaz F. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. *Schizophr Res*. 2005; 76:135–157. [PubMed: 15949648]
- de Leon J, Becoña E, Gurpegui M, Gonzalez-Pinto A, Diaz FJ. The association between high nicotine dependence and severe mental illness may be consistent across countries. *J Clin Psychiatry*. 2002a; 63:812–816. [PubMed: 12363123]
- de Leon J, Diaz FJ, Rogers T, Browne D, Dinsmore L. Initiation of daily smoking and nicotine dependence in schizophrenia and mood disorders. *Schizophr Res*. 2002b; 56:47–54. [PubMed: 12084419]

- de Leon J, Tracy J, McCann E, McGrory A, Diaz FJ. Schizophrenia and tobacco smoking: a replication study in another US psychiatric hospital. *Schizophr Res*. 2002c; 56:55–65. [PubMed: 12084420]
- de Leon J, Diaz FJ, Becoña E, Gurpegui M, Jurado D, Gonzalez-Pinto A. Exploring brief measures of nicotine dependence for epidemiological surveys. *Addict Behav*. 2003; 28:1481–1486. [PubMed: 14512071]
- de Leon J, Susce MT, Diaz FJ, Rendon DM, Velasquez DM. Variables associated with alcohol, drug and daily smoking cessation in patients with severe mental illnesses. *J Clin Psychiatry*. 2005; 66:1447–1455. [PubMed: 16420083]
- de Leon J, Diaz FJ, Aguilar MC, Jurado D, Gurpegui M. Does smoking reduce akathisia?: Testing a narrow version of the self-medication hypothesis. *Schizophr Res*. 2006; 86:256–268. [PubMed: 16814524]
- de Leon J, Gurpegui M, Diaz FJ. Epidemiology of comorbid tobacco use and schizophrenia: thinking about risks and protective factors. *J Dual Diagn*. 2007a; 3:9–25.
- de Leon J, Rendon DM, Baca-Garcia E, Aizpuru F, Gonzalez-Pinto A, Anitua C, Diaz FJ. Association between smoking and alcohol use in the general population: stable and unstable odds ratios across two years in two different countries. *Alcohol Alcohol*. 2007b; 42:252–257. [PubMed: 17526636]
- Degenhardt L, Hall W. The relationship between tobacco use, substance-use disorders and mental health: results from the national survey of mental health and well-being. *Nicotine Tob Res*. 2001a; 3:225–234. [PubMed: 11506766]
- Degenhardt L, Hall W. The association between psychosis and problematical drug use among Australian adults: Wndings from the national survey of mental health and well-being. *Psychol Med*. 2001b; 31:659–668. [PubMed: 11352368]
- Degenhardt L, Hall W, Lynskey M. Alcohol, cannabis and tobacco use among Australians: a comparison of their associations with other drug use and use disorders, affective and anxiety disorders, and psychosis. *Addiction*. 2001; 96:1603–1614. [PubMed: 11784457]
- Degenhardt L, Chiu WT, Sampson N, Kessler RC, Anthony JC, Anger-meyer M, Bruffaerts R, de Girolamo G, Gureje O, Huang Y, Karam A, Kostyuchenko S, Lepine JP, Mora ME, Neumark Y, Ormel JH, Pinto-Meza A, Posada-Villa J, Stein DJ, Takeshima T, Wells JE. Toward a global view of alcohol, tobacco, cannabis, and cocaine use: Wndings from the WHO World Mental Health Surveys. *PLoS Med*. 2008; 5:e141. [PubMed: 18597549]
- Degenhardt L, Dierker L, Chiu WT, Medina-Mora ME, Neumark Y, Sampson N, Alonso J, Angermeyer M, Anthony JC, Bruffaerts R, de Girolamo G, de Graaf R, Gureje O, Karam AN, Kostyuchenko S, Lee S, Lépine JP, Levinson D, Nakamura Y, Posada-Villa J, Stein D, Wells JE, Kessler RC. Evaluating the drug use “gateway” theory using cross-national data: consistency and associations of the order of initiation of drug use among participants in the WHO World Mental Health Surveys. *Drug Alcohol Depend*. 2010; 108:84–97. [PubMed: 20060657]
- Diaz FJ, Jané M, Saltó E, Pardell H, Salleras L, Pinet C, de Leon J. A brief measure of high nicotine dependence for busy clinicians and large epidemiological surveys. *Aust N Z J Psychiatry*. 2005; 39:161–168. [PubMed: 15701065]
- Diaz FJ, Velasquez DM, Susce MT, de Leon J. The association between schizophrenia and smoking: unexplained by either the illness or the prodromal period. *Schizophr Res*. 2008; 104:214–219. [PubMed: 18650069]
- Diaz FJ, James D, Botts S, Maw L, Susce MT, de Leon J. Tobacco smoking behaviors in bipolar disorder: a comparison with the general population, schizophrenia and major depression. *Bipolar Disord*. 2009; 11:154–165. [PubMed: 19267698]
- Dick DM, Meyers JL, Rose RJ, Kaprio J, Kendler KS. Measures of current alcohol consumption and problems: two independent twin studies suggest a complex genetic architecture. *Alcohol Clin Exp Res*. 2011 (Epub ahead of print).
- Dierker L, He J, Kalaydjian A, Swendsen J, Degenhardt L, Glantz M, Conway K, Anthony J, Chiu WT, Sampson NA, Kessler R, Merikangas K. The importance of timing of transitions for risk of regular smoking and nicotine dependence. *Ann Behav Med*. 2008; 36:87–92. [PubMed: 18704617]
- Döme P, Rihmer Z, Gonda X, Pestality P, Kovács G, Teleki Z, Mandl P. Cigarette smoking and psychiatric disorders in Hungary. *Int J Psychiatry Clin Pract*. 2005; 9:145–148.

- Edwards AC, Kendler KS. Nicotine withdrawal-induced negative affect is a function of nicotine dependence and not liability to depression or anxiety. *Nicotine Tob Res.* 2011; 13:677–685. [PubMed: 21504882]
- Edwards AC, Maes HH, Pedersen NL, Kendler KS. A population-based twin study of the genetic and environmental relationship of major depression, regular tobacco use and nicotine dependence. *Psychol Med.* 2011; 41:395–405. [PubMed: 20406522]
- Esterberg ML, Jones EM, Compton MT, Walker EF. Nicotine consumption and schizotypy in first-degree relatives of individuals with schizophrenia and non-psychiatric controls. *Schizophr Res.* 2007; 97:6–13. [PubMed: 17897810]
- Falk DE, Yi HY, Hiller-Sturmhöfel S. An epidemiologic analysis of co-occurring alcohol and tobacco use and disorders: findings from the national epidemiologic survey on alcohol and related conditions. *Alcohol Res Health.* 2006; 29:162–171. [PubMed: 17373404]
- Fanous AH, Neale MC, Gardner CO, Webb BT, Straub RE, O'Neill FA, Walsh D, Riley BP, Kendler KS. Significant correlation in linkage signals from genome-wide scans of schizophrenia and schizotypy. *Mol Psychiatry.* 2007; 12:958–965. [PubMed: 17440434]
- Freedman R, Coon H, Myles-Worsley M, Orr-Urtreger A, Olincy A, Davis A, Polymeropoulos M, Holik J, Hopkins J, Hoff M, Rosenthal J, Waldo MC, Reimherr F, Wender P, Yaw J, Young DA, Breese CR, Adams C, Patterson D, Adler LE, Kruglyak L, Leonard S, Byerley W. Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. *Proc Natl Acad Sci USA.* 1997; 94:587–592. [PubMed: 9012828]
- Gejman PV, Sanders AR, Kendler KS. Genetics of schizophrenia: new findings and challenges. *Annu Rev Genomics Hum Genet.* 2011; 12:121–144. [PubMed: 21639796]
- Gershon Grand RB, Hwang S, Han J, George T, Brody AL. Short-term naturalistic treatment outcomes in cigarette smokers with substance abuse and/or mental illness. *J Clin Psychiatry.* 2007; 68:892–898. [PubMed: 17592914]
- González-Pinto A, Alberich S, Ruiz de Azúa S, Martínez-Cengotitabengoa M, Fernández M, Gutiérrez M, Saenz M, Besga A, Galdós P, de Leon J. Psychosis and smoking cessation: difficulties in quitting associated with sex and substance abuse. *Psychiatry Res.* 2011 (Epub ahead of print).
- Grant BF, Hasin DS, Chou SP, Stinson FS, Dawson DA. Nicotine dependence and psychiatric disorders in the United States: results from the national epidemiologic survey on alcohol and related conditions. *Arch Gen Psychiatry.* 2004; 61:1107–1115. [PubMed: 15520358]
- Greenland S, Drescher K. Maximum likelihood estimation of the attributable fraction from logistic models. *Biometrics.* 1993; 49:865–872. [PubMed: 8241375]
- Gurpegui M, Martínez-Ortega JM, Aguilar MC, Diaz FJ, Quintana HM, de Leon J. Smoking initiation and schizophrenia: a replication study in a Spanish sample. *Schizophr Res.* 2005; 76:113–118. [PubMed: 15927805]
- Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström test for nicotine dependence: a revision of the Fagerström tolerance questionnaire. *Br J Addict.* 1991; 86:1119–1127. [PubMed: 1932883]
- Heatherton TF, Kozlowski LT, Frecker RC, Rickert W, Robinson J. Measuring the heaviness of smoking: using self-reported time to the first cigarette of the day and number of cigarettes per day. *Br J Addict.* 1998; 84:791–800. [PubMed: 2758152]
- Henningfeld JE, Cohen C, Slade J. Is nicotine more addictive than cocaine? *Br J Addict.* 1991; 86:565–569. [PubMed: 1859920]
- Hitsman B, Borrelli B, McChargue DE, Spring B, Niaura R. History of depression and smoking cessation outcome: a meta-analysis. *J Consult Clin Psychol.* 2003; 71:657–663. [PubMed: 12924670]
- Hughes JR. An overview of nicotine use disorders for alcohol/drug abuse clinicians. *AJA.* 1996; 5:262–273.
- Hughes JR, Hatsukamy DK, Mitchell JE, Dahlgren LA. Prevalence of smoking among psychiatric outpatients. *Am J Psychiatry.* 1986; 143:993–997. [PubMed: 3487983]
- Ioannidis JP. Why most published research findings are false. *PLoS Med.* 2005; 2(8):e124. [PubMed: 16060722]

- Itkin O, Nemets B, Einat H. Smoking habits in bipolar and schizophrenic outpatients in southern Israel. *J Clin Psychiatry*. 2001; 63:368–369.
- Jones RM, Lichtenstein P, Grann M, Långström N, Fazel S. Alcohol use disorders in schizophrenia: a national cohort study of 12,653 patients. *J Clin Psychiatry*. 2011; 72:775–779. [PubMed: 21733478]
- Kalman D, Morissette SB, George TP. Co-morbidity of smoking in patients with psychiatric and substance use disorders. *Am J Addict*. 2005; 14:106–123. [PubMed: 16019961]
- Kendler KS, Schaffner KF. The dopamine hypothesis of schizophrenia: an historical and philosophical analysis. *Philos Psychiatry Psychol*. 2011; 18:41–63.
- Kendler KS, Neale MC, MacLean CJ, Heath AC, Eaves LJ, Kessler RC. Smoking and major depression: a causal analysis. *Arch Gen Psychiatry*. 1993; 50:36–43. [PubMed: 8422220]
- Kendler KS, Prescott CA, Myers J, Neale MC. The structure of genetic and environmental risk factors for common psychiatric and substance use disorders in men and women. *Arch Gen Psychiatry*. 2003; 60:929–937. [PubMed: 12963675]
- Kendler KS, Gardner C, Jacobson KC, Neale MC, Prescott CA. Genetic and environmental influences on illicit drug use and tobacco use across birth cohorts. *Psychol Med*. 2005; 3:1349–1356. [PubMed: 16168157]
- Kendler KS, Myers J, Prescott CA. Specificity of genetic and environmental risk factors for symptoms of cannabis, cocaine, alcohol, caffeine, and nicotine dependence. *Arch Gen Psychiatry*. 2007; 64:1313–1320. [PubMed: 17984400]
- Kendler KS, Schmitt E, Aggen SH, Prescott CA. Genetic and environmental influences on alcohol, caffeine, cannabis, and nicotine use from early adolescence to middle adulthood. *Arch Gen Psychiatry*. 2008; 65:674–682. [PubMed: 18519825]
- Kendler KS, Gardner CO, Prescott CA. Toward a comprehensive developmental model for alcohol use disorders in men. *Twin Res Hum Genet*. 2011; 14:1–15. [PubMed: 21314251]
- Khantzian EJ. The self-medication hypothesis of addictive disorders: focus on heroin and cocaine dependence. *Am J Psychiatry*. 1985; 142:1259–1264. [PubMed: 3904487]
- Kobayashi M, Ito H, Okumura Y, Mayahara K, Matsumoto Y, Hirakawa J. Hospital readmission in first-time admitted patients with schizophrenia: smoking patients had higher hospital readmission rate than non-smoking patients. *Int J Psychiatry Med*. 2010; 40:247–257. [PubMed: 21166336]
- Kolb GF, Le Moal M. Drug abuse: hedonic homeostatic dysregulation. *Science*. 1997; 278:52–58. [PubMed: 9311926]
- Koob GF, Volkow ND. Neurocircuitry of addiction. *Neuropsychopharmacology*. 2010; 35:217–238. [PubMed: 19710631]
- Koskinen J, Löhönen J, Koponen H, Isohanni M, Miettunen J. Prevalence of alcohol use disorders in schizophrenia—a systematic review and meta-analysis. *Acta Psychiatr Scand*. 2009; 120:85–96. [PubMed: 19374633]
- Koskinen J, Löhönen J, Koponen H, Isohanni M, Miettunen J. Rate of cannabis use disorders in clinical samples of patients with schizophrenia: a meta-analysis. *Schizophr Bull*. 2010; 36:1115–1130. [PubMed: 19386576]
- Kozlowski LT, Ferrence RG, Corbit T. Tobacco use: a perspective for alcohol and drug researchers. *Br J Addict*. 1990; 85:245. [PubMed: 2317591]
- Lasser K, Boyd JW, Woolhandler S, Himmelstein DD, McCormick D, Bor DH. Smoking and mental illness: a population-based prevalence study. *JAMA*. 2000; 284:2606–2610. [PubMed: 11086367]
- Lawrence D, Mitrou F, Zubrick SR. Smoking and mental illness: results from population surveys in Australia and the United States. *BMC Public Health*. 2009; 9:285. [PubMed: 19664203]
- Lessov-Schlaggar CN, Pang Z, Swan GE, Guo Q, Wang S, Cao W, Unger JB, Johnson CA, Lee L. Heritability of cigarette smoking and alcohol use in Chinese male twins: the Qingdao twin registry. *Int J Epidemiol*. 2006; 35:1278–1285. [PubMed: 16847025]
- Li MD, Ma JZ, Beuten J. Progress in searching for susceptibility loci and genes for smoking-related behaviour. *Clin Genet*. 2004; 66:382–392. [PubMed: 15479180]
- Lo S, Heishman SJ, Raley H, Wright K, Wehring HJ, Moolchan ET, Feldman S, Liu F, McMahon RP, Richardson CM, Kelly DL. Tobacco craving in smokers with and without schizophrenia. *Schizophr Res*. 2011; 127:241–245. [PubMed: 20637571]

- Lohr JB, Flynn K. Smoking and schizophrenia. *Schizophr Res.* 1992; 8:93–102. [PubMed: 1360812]
- Lopez-Quintero C, Pérez de los Cobos J, Hasin DS, Okuda M, Wang S, Grant BF, Blanco C. Probability and predictors of transition from first use to dependence on nicotine, alcohol, cannabis, and cocaine: results of the national epidemiologic survey on alcohol and related conditions (NESARC). *Drug Alcohol Depend.* 2011; 115:120–130. [PubMed: 21145178]
- McClave AK, McKnight-Eily LR, Davis SP, Dube SR. Smoking characteristics of adults with selected lifetime mental illnesses: results from the 2007 national health interview survey. *Am J Public Health.* 2010; 100:2464–2472. [PubMed: 20966369]
- McKee SA, Falba T, O'Malley SS, Sindelar J, O'Connor PG. Smoking status as a clinical indicator for alcohol misuse in US adults. *Arch Intern Med.* 2007; 167:716–721. [PubMed: 17420431]
- McKee SA, Weinberger AH, Harrison EL, Coppola S, George TP. Effects of the nicotinic receptor antagonist mecamylamine on ad-lib smoking behavior, topography, and nicotine levels in smokers with and without schizophrenia: a preliminary study. *Schizophr Res.* 2009; 115:317–324. [PubMed: 19700263]
- Mexal S, Berger R, Logel J, Ross RG, Freedman R, Leonard S. Differential regulation of alpha7 nicotinic receptor gene (CHRNA7) expression in schizophrenic smokers. *J Mol Neurosci.* 2010; 40:185–195. [PubMed: 19680823]
- Mori T, Sasaki T, Iwanami A, Mizuno K, Kato T, Kato N. Smoking habits in Japanese patients with schizophrenia. *Psychiatry Res.* 2003; 120:207–209. [PubMed: 14527652]
- National Advisory Mental Health Council. Health care reform for Americans with severe mental illnesses: report of the National Advisory Mental Health Council. *Am J Psychiatry.* 1993; 150:1447–1465. [PubMed: 8379547]
- Nelson CB, Wittchen HU. Smoking and nicotine dependence: results from a sample of 14- to 24 year-olds in Germany. *Eur Addict Res.* 1998; 4:42–49. [PubMed: 9740816]
- Niaura, R.; Shiffman, S. Psychosocial and biological mechanism.. In: Ferting, JB.; Allen, JP., editors. *Alcohol and tobacco: From basic science to clinical practice*, NIH Publication 95-397. United States Department of Health and Human Services; Washington, DC: 1995. p. 159-168.
- Nuechterlein KH, Asarnow RF, Subotnik KL, Fogelson DL, Payne DL, Kendler KS, Neale MC, Jacobson KC, Mintz J. The structure of schizotypy: relationships between neurocognitive and personality disorder features in relatives of schizophrenic patients in the UCLA family study. *Schizophr Res.* 2002; 54:121–130. [PubMed: 11853986]
- Olinicy A, Young DA, Freedman R. Increased levels of the nicotine metabolite cotinine in schizophrenic smokers compared to other smokers. *Biol Psychiatry.* 1997; 42:1–5. [PubMed: 9193735]
- Patkar AA, Mannelli P, Peindl K, Murray HW, Meier B, Leone FT. Changes in tobacco smoking following treatment for cocaine dependence. *Am J Drug Alcohol Abuse.* 2006; 32:135–148. [PubMed: 16595320]
- Prochaska JJ, Hall SM, Bero LA. Tobacco use among individuals with schizophrenia: what role has the tobacco industry played? *Schizophr Bull.* 2008; 34:555–567. [PubMed: 17984298]
- Regier DA, Farmer ME, Rae DS, Myers JK, Kramer M, Robins LN, George LK, Karno M, Locke BZ. Comorbidity of mental disorders with alcohol and other drug abuse: results from the epidemiologic catchment area (ECA) study. *JAMA.* 1990; 264:2511–2518. [PubMed: 2232018]
- Rendu F, Peoc'h K, Berlin I, Thomas D, Launay JM. Smoking related diseases: the central role of monoamine oxidase. *Int J Environ Res Public Health.* 2011; 8:136–147. [PubMed: 21318020]
- Richter KP, Arnsten JH. A rationale and model for addressing tobacco dependence in substance abuse treatment. *Subst Abuse Treat Prev Policy.* 2006; 1:23. [PubMed: 16907984]
- Richter KP, Ahluwalia HK, Mosier MC, Nazir N, Ahluwalia JS. A population-based study of cigarette smoking among illicit drug users in the United States. *Addiction.* 2002; 97:861–869. [PubMed: 12133125]
- Rohde P, Lewinsohn PM, Brown RA, Gau JM, Kahler CW. Psychiatric disorders, familial factors and cigarette smoking: I. Associations with smoking initiation. *Nicotine Tob Res.* 2003; 5:85–98. [PubMed: 12745510]

- Rohde P, Kahler CW, Lewinsohn PM, Brown RA. Psychiatric disorders, familial factors, and cigarette smoking: II. associations with progression to daily smoking. *Nicotine Tob Res.* 2004; 6:119–132. [PubMed: 14982696]
- Room R. Smoking and drinking as complementary behaviors. *Biomed Pharmacother.* 2004; 58:111–115. [PubMed: 14992792]
- Rose, RJ.; Boms, U.; Korhonen, T.; Dick, DM.; Kaprio, J. Genetics of smoking behavior.. In: Kim, YK., editor. *Handbook of behavior genetics*. Springer; New York: 2008. p. 411-432.
- Salin-Pascual RJ, Rosas M, Jiménez-Genchi A, Rivera-Meza BL, Delgado-Perra V. Antidepressant effect of transdermal nicotine patches in nonsmoking patients with major depression. *J Clin Psychiatry.* 1996; 57:387–389. [PubMed: 9746444]
- Salokangas RK, Honkonen T, Stengård E, Koivisto AM, Hietala J. Cigarette smoking in long-term schizophrenia. *Eur Psychiatry.* 2006; 21:219–223. [PubMed: 16360309]
- Schiffman, S.; Balabanis, M. Associations between alcohol and tobacco.. In: Ferting, JB.; Allen, JP., editors. *Alcohol and tobacco: From basic science to clinical practice*, NIH Publication 95-397. United States Department of Health and Human Services; Washington, DC: 1995. p. 17-36.
- Segarra R, Zabala A, Eguíluz JI, Ojeda N, Elizagarate E, Sánchez P, Ballesteros J, Gutiérrez M. Cognitive performance and smoking in first-episode psychosis: the self-medication hypothesis. *Eur Arch Psychiatry Clin Neurosci.* 2011; 261:241–250. [PubMed: 20839003]
- Shiffman S. Tobacco “chippers”—individual differences in tobacco dependence. *Psychopharmacology (Berl).* 1989; 97:539–547. [PubMed: 2498951]
- Shiffman S. Light and intermittent smokers: background and perspective. *Nicotine Tob Res.* 2009; 11:122–125. [PubMed: 19246630]
- Shinozaki Y, Nakao M, Takeuchi T, Yano E. Smoking rates among schizophrenia patients in Japan. *Psychiatry Res.* 2010; 186:165–169. [PubMed: 20817269]
- Soltz H, Crockford D, White WD, Currie S. Cigarette smoking, nicotine dependence, and motivation for smoking cessation in psychiatric inpatients. *Can J Psychiatry.* 2009; 54:36–45. [PubMed: 19175978]
- StataCorp.. *Stata: Release 11. Statistical Software*. StataCorp LP; College Station, TX: 2009.
- Steinberg ML, Williams JM, Steinberg HR, Krejci JA, Ziedonis DM. Applicability of the Fagerström test for nicotine dependence in smokers with schizophrenia. *Addict Behav.* 2005; 30:49–59. [PubMed: 15561448]
- Stewart DW, Cohen AS, Copeland AL. Cigarette smoking across the schizotypy spectrum. *Psychiatry Res.* 2010; 179:113–115. [PubMed: 20483483]
- Strand JE, Nybäck H. Tobacco use in schizophrenia: a study of cotinine concentrations in the saliva of patients and controls. *Eur Psychiatry.* 2005; 20:50–54. [PubMed: 15642444]
- Suárez M, Haydar R, Campo A, Bermúdez A, Ayola C. Tabaquismo y trastornos mentales. *Acta Médica Colombiana.* 1996; 21:317–321.
- Sullivan PF, Kendler KS, Neale MC. Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. *Arch Gen Psychiatry.* 2003; 60:1187–1192. [PubMed: 14662550]
- Swan GE, Carmelli D, Rosenman RH, Fabsitz RR, Christian JC. Smoking and alcohol consumption in adult male twins: genetic heritability and shared environmental influences. *J Subst Abuse.* 1990; 2:39–50. [PubMed: 2136102]
- Swan GE, Carmelli D, Cardon LR. Heavy consumption of cigarettes, alcohol and coffee in male twins. *J Stud Alcohol.* 1997; 58:182–190. [PubMed: 9065896]
- Swartz MS, Wagner HR, Swanson JW, Stroup TS, McEvoy JP, Canive JM, Miller DD, Reimherr F, McGee M, Khan A, Van Dorn R, Rosenheck RA, Lieberman JA. Substance use in persons with schizophrenia: baseline prevalence and correlates from the NIMH CATIE study. *J Nerv Ment Dis.* 2006; 19:164–172. [PubMed: 16534433]
- Tidey JW, Rohsenow DJ, Kaplan GB, Swift RM. Cigarette smoking topography in smokers with schizophrenia and matched non-psychiatric controls. *Drug Alcohol Depend.* 2005; 80:259–265. [PubMed: 15869844]
- Tsoi DT, Porwal M, Webster AC. Interventions for smoking cessation and reduction in individuals with schizophrenia. *Cochrane Database Syst Rev.* 2010; 6:CD007253. [PubMed: 20556777]

- Tyndale RF. Genetics of alcohol and tobacco use in humans. *Ann Med*. 2003; 35:94–121. [PubMed: 12795339]
- van Os J, Kenis G, Rutten BP. The environment and schizophrenia. *Nature*. 2010; 468:203–212. [PubMed: 21068828]
- Vanyukov MM, Kirisci L, Moss L, Tarter RE, Reynolds MD, Maher BS, Kirillova GP, Ridenour T, Clark DB. Measurement of the risk for substance use disorders: phenotypic and genetic analysis of an index of common liability. *Behav Genet*. 2009; 39:233–244. [PubMed: 19377872]
- Volkow ND. Substance use disorders in schizophrenia—clinical implications of comorbidity. *Schizophr Bull*. 2009; 35:469–472. [PubMed: 19325163]
- Volkow ND, Fowler JS. Addiction, a disease of compulsion and drive: involvement of the orbitofrontal cortex. *Cereb Cortex*. 2000; 10:318–325. [PubMed: 10731226]
- Volkow N, Li TK. The neuroscience of addiction. *Nat Neurosci*. 2005; 8:1429–1430. [PubMed: 16251981]
- Wagner FA, Anthony JC. Into the world of illegal drug use: exposure opportunity and other mechanisms linking the use of alcohol, tobacco, marijuana, and cocaine. *Am J Epidemiol*. 2002; 155:918–925. [PubMed: 11994231]
- Wang CY, Xiang YT, Weng YZ, Bo QJ, Chiu HF, Chan SS, Lee EH, Ungvari GS. Cigarette smoking in patients with schizophrenia in China: prospective, multicentre study. *Aust N Z J Psychiatry*. 2010; 44:456–462. [PubMed: 20397788]
- Weinberger AH, Sacco KA, Creeden CL, Vessicchio JC, Jatlow PI, George TP. Effects of acute abstinence, reinstatement, and mecamylamine on biochemical and behavioral measures of cigarette smoking in schizophrenia. *Schizophr Res*. 2007; 9:217–225. [PubMed: 17293085]
- Weinberger AH, Desai RA, McKee SA. Nicotine withdrawal in US smokers with current mood, anxiety, alcohol use, and substance use disorders. *Drug Alcohol Depend*. 2010; 108:7–12. [PubMed: 20006451]
- Weinberger AH, George TP, McKee SA. Differences in smoking expectancies in smokers with and without a history of major depression. *Addict Behav*. 2011; 6:434–437. [PubMed: 21239119]
- Westermeyer J. Comorbid schizophrenia and substance abuse: a review of epidemiology and course. *Am J Addict*. 2006; 15:345–355. [PubMed: 16966190]
- Widome R, Linde JA, Rohde P, Ludman EJ, Jeffery RW, Simon GE. Does the association between depression and smoking vary by body mass index (BMI) category? *Prev Med*. 2009; 49:380–383. [PubMed: 19647015]
- Williams JM, Ziedonis DM, Abanyie F, Steinberg ML, Foulds J, Benowitz NL. Increased nicotine and cotinine levels in smokers with schizophrenia and schizoaffective disorder is not a metabolic effect. *Schizophr Res*. 2005; 79:323–335. [PubMed: 15961287]
- Williams JM, Gandhi KK, Lu SE, Kumar S, Shen J, Foulds J, Kipen H, Benowitz NL. Higher nicotine levels in schizophrenia compared with controls after smoking a single cigarette. *Nicotine Tob Res*. 2010; 12:855–859. [PubMed: 20584771]
- Williams JM, Gandhi KK, Lu SE, Kumar S, Steinberg ML, Cottler B, Benowitz NL. Shorter interpuft interval is associated with higher nicotine intake in smokers with schizophrenia. *Drug Alcohol Depend*. 2011 (Epub).
- Xian H, Scherrer JF, Madden PA, Lyons MJ, Tsuang M, True WR, Eisen SA. Latent class typology of nicotine withdrawal: genetic contributions and association with failed smoking cessation and psychiatric disorders. *Psychol Med*. 2005; 35:409–419. [PubMed: 15841876]
- Xian H, Scherrer JF, Grant JD, Eisen SA, True WR, Jacob T, Bucholz KK. Genetic and environmental contributions to nicotine, alcohol and cannabis dependence in male twins. *Addiction*. 2008; 103:1391–1398. [PubMed: 18855830]
- Ystrom E, Reichborn-Kjennerud T, Aggen SH, Kendler KS. Alcohol dependence in men: reliability and heritability. *Alcohol Clin Exp Res*. 2011 (Epub ahead of print).
- Zhang XY, Li CB, Li M, Zheng YL, Zhang CX, Yan QZ, Liu WZ, Kang YM, Wang F, da Chen C, Xiu MH, Kosten TR. Smoking initiation and schizophrenia: a replication study in a Chinese Han population. *Schizophr Res*. 2010; 119:110–114. [PubMed: 20022218]

- Ziedonis DM, George TP. Schizophrenia and nicotine use: report of a pilot smoking cessation program and review of neuro-biological and clinical issues. *Schizophr Bull.* 1997; 23:247–254. [PubMed: 9165635]
- Ziedonis D, Hitsman B, Beckham JC, Zvolensky M, Adler LE, Audrain-McGovern J, Breslau N, Brown RA, George TP, Williams J, Calhoun PS, Riley WT. Tobacco use and cessation in psychiatric disorders: national institute of mental health report. *Nicotine Tob Res.* 2008; 10:1691–1715. [PubMed: 19023823]

\$watermark-text

\$watermark-text

\$watermark-text

STAGE 1: Are the genetic-variation frequencies significantly higher¹ in ever daily smokers than in non-ever daily smokers within...

STAGE 2: Do genetic-variation frequencies significantly satisfy the inequality¹...

STAGE 3: Within schizophrenia ever-daily smokers, do genetic-variation frequencies significantly satisfy the inequality¹...

¹ The figure describes gene variations that are risk factors for an increased risk of ever daily smoking. For associated protective genes, the frequency inequalities in the three stages will exhibit the opposite pattern. Protective genes will exhibit (1) lower frequencies in ever daily smokers than in non-ever daily smokers within non-psychiatric controls (hypothesis 1), bipolar controls (hypothesis 2), and schizophrenia cases (hypothesis 3); (2) lower frequencies in schizophrenia cases than in bipolar controls (hypothesis 4), and in bipolar controls than in non-psychiatric controls (hypothesis 5); and (3) lower frequencies in late onset than in early onset schizophrenia daily smokers (hypothesis 6).

² Late onset of ever daily smoking: ≥ 20 years of age. Early onset of ever daily smoking: <20 years of age.

Fig. 1.
Schematic representation of a proposed three-stage approach for searching genes explaining the increased risk of ever daily smoking seen in schizophrenia

Table 1

Summary of meta-analysis (de Leon and Diaz, 2005) on the association between schizophrenia and different smoking behaviors: odds ratios (ORs) and consistency

	Study consistency ^a			Countries		Average ORs (95% CI)		
	N	OR > 1	+Significant	N ^b	Type ^c	Total sample	Male	Female
↑ Current smoking versus general population	42	40/42	37/42	20	Some non-Western	5.3 (4.9–5.7)		
	32	29/32	29/32	18	Most Western		7.2 (6.1–8.3)	
	25	20/25	20/25	15	Most Western			3.3 (3.0–3.6)
↑ Current smoking versus other SMIs	18	17/18	14/18	9	Most Western	1.9 (1.7–2.1)		
	14	11/14	11/14	8	Most Western		2.3 (2.0–2.7)	
↑ Ever smoking versus general population	8	6/8	3/8	5	Western			1.8 (1.5–2.3)
	9	8/9	8/9	6	Western	3.1 (2.4–3.8)		
	4	4/4	3/4	3	Western		7.3 (1.04–13.6)	
↑ Ever smoking versus other SMIs	3	3/3	2/3	3	Western			2.8 (1.2–4.4)
	5	4/5	3/5	5	Most Western	2.0 (1.6–2.4)		
	4	4/4	2/4	3	Most Western		2.0 (1.5–2.7)	
↓ Smoking cessation in ever smokers versus general population	2	1/2	0/2	2	Western			0.92 (0.44–1.9)
	6	6/6	6/6	5	Western	5.3 (4.2–7.1)		
	4	4/4	4/4	3	Western		10.0 (7.1–16.7)	
↓ Smoking cessation in ever smokers versus other SMIs	3	3/3	2/3	3	Western			2.2 (1.5–4.3)
	4	3/4	1/4	4	Western	1.8 (1.1–3.0)		
	4	4/4	3/4	3	Most Western		2.9 (1.9–13.4)	
	2	0/2	0/2	2	Western			0.37 (0.11–1.3)

CI 95% confidence interval

^a N, number of studies; OR > 1, number of individual studies with OR > 1 divided by N; +Significant, number of individual studies with significant OR > 1 divided by N

^b N, number of countries

^c USA, Canada, European countries, and Israel are considered Western countries

Table 2

Association between smoking behaviors and schizophrenia: a summary focused on various definitions and their potential for genetic studies

Smoking behavior definition	Control	Results	Potential
↑ Current daily smoking	General population	Very strong and consistent association worldwide	Complex: ↑initiation and/or ↓ cessation
	Other SMIs	Good, but limited data from non-Western countries	Complex: ↑initiation and/or ↓ cessation
↑ Ever daily smoking	General population	Good, but no data from non-Western countries	Differences partly due to SMI confounders
	Other SMIs	Supported by very few Western studies	Best potential
↓ Cessation in daily smokers	General population	Supported by very few Western studies	Differences may be due to heavy smoking
	Other SMIs	No data in favor: it may not be true	No proof of association
↑ Heavy smoking in daily smokers	General population	Supported by a few Western studies	Differences partly due to SMI confounders
	Other SMIs	Few inconsistent studies	No proof of association
↑ Nicotine dependence in smokers	General population	Supported by a few Western studies	Differences partly due to SMI confounders
	Other SMIs	Few inconsistent studies	No proof of association

SMI severe mental illness

Table 3
Odds ratios (ORs) comparing frequencies of ever smoking in patients with schizophrenia versus bipolar disorder

Authors	Country	Type	Schizophrenia	Bipolar disorder	OR	CI
Ever smoking in samples including both genders						
Döme et al. (2005)	Hungary	Outpatients	75% (91/122)	70% (42/60)	1.3	(0.63, 2.5)
Itkin et al. (2001)	Israel	Outpatients	55% (35/64)	60% (42/70)	0.83	(0.40, 1.6)
de Leon et al. (2002a)	USA	Inpatients	91% (62/68)	83% (24/29)	2.1	(0.59, 7.7)
Diaz et al. (2009)	USA	In/outpatients	83% (215/258)	74% (73/99)	1.8	(1.02, 3.1)
Total of 4 samples	3 Countries		79% (403/512)	70% (181/258)	1.6	(1.1, 2.2)
Ever smoking in males						
Döme et al. (2005)	Hungary	Outpatients	74% (46/62)	77% (20/26)	0.83	(0.29, 2.5)
Itkin et al. (2001)	Israel	Outpatients	71% (22/31)	62% (20/32)	1.5	(0.50, 4.2)
de Leon et al. (2002a)	USA	Inpatients	95% (41/43)	88% (14/16)	2.9	(0.37, 25.0)
Diaz et al. (2009)	USA	In/outpatients	86% (127/148)	87% (40/46)	0.91	(0.34, 2.4)
Total of 4 samples	3 Countries		83% (236/284)	78% (94/120)	1.4	(0.77, 2.3)
Ever smoking in females						
Döme et al. (2005)	Hungary	Outpatients	75% (45/60)	65% (22/34)	1.6	(0.67, 4.0)
Itkin et al. (2001)	Israel	Outpatients	39% (13/33) ^a	58% (22/38)	0.48	(0.18, 1.22)
de Leon et al. (2002a)	USA	Inpatients	84% (21/25)	77% (10/13)	1.6	(0.29, 8.3)
Diaz et al. (2009)	USA	In/outpatients	80% (88/110)	62% (33/53)	2.4	(1.2, 5.0)
Total of 4 samples	3 Countries		73% (167/228)	63% (87/138)	1.6	(1.0, 2.5)

CI 95% confidence interval

^aThe study included a small subsample of female schizophrenia patients with an unusual ethnic background who smoked less than the Israeli female general population

\$watermark-text

\$watermark-text

\$watermark-text

Table 4
Odds ratios (ORs) comparing frequencies of ever smoking in patients with schizophrenia versus major depressive disorder

Author	Country	Type	Schizophrenia	Major depressive disorder	OR	CI
Ever smoking in samples including both genders						
Döme et al. (2005)	Hungary	Outpatients	75% (91/122)	70% (64/92)	1.3	(0.70, 2.3)
de Leon et al. (2002a)	USA	Inpatients	91% (62/68)	73% (16/22)	3.9	(1.1, 13.6)
Diaz et al. (2009)	USA	In/outpatients	83% (215/258)	75% (50/67)	1.7	(0.90, 3.2)
Total of 3 samples	2 Countries		82% (368/448)	72% (130/181)	1.8	(1.2, 2.7)
Ever smoking in males						
Döme et al. (2005)	Hungary	Outpatients	74% (46/62)	75% (24/32)	0.96	(0.36, 2.6)
de Leon et al. (2002a)	USA	Inpatients	95% (41/43)	87% (13/15)	3.2	(0.40, 24.7)
Diaz et al. (2009)	USA	In/outpatients	86% (127/148)	74% (17/23)	2.1	(0.76, 6.0)
Total of 3 samples	2 Countries		85% (214/253)	77% (54/70)	1.6	(0.85, 3.1)
Ever smoking in females						
Döme et al. (2005)	Hungary	Outpatients	75% (45/60)	67% (40/60)	1.5	(0.68, 3.3)
de Leon et al. (2002a)	USA	Inpatients	84% (21/25)	43% (3/7)	7.0	(1.1, 44.1)
Diaz et al. (2009)	USA	In/outpatients	80% (88/110)	75% (33/44)	1.3	(0.58, 3.0)
Total of 3 samples	2 Countries		79% (154/195)	68% (76/111)	1.7	(1.02, 2.9)
CI 95% confidence interval						

Table 5

Adjusted odds ratios (ORs), their confidence intervals (CIs) and population attributable risks (PARs) for ever smoking

Factor	Adjusted OR (CI)	Prevalence (P), (%)	PAR (%)
In the general population (de Leon et al. 2007b) ^a			
Lifetime alcohol use (USA, 1992)	6.2 (4.4–8.8)	88	82
Lifetime alcohol use (USA, 1996)	9.8 (7.5–12.8)	88	89
Lifetime alcohol use (Basque country, ^b 1992)	3.0 (2.3–3.9)	86	63
Lifetime alcohol use (Basque country, ^b 1996)	2.6 (2.1–3.3)	83	57
In patients with severe mental illness (SMI) (<i>N</i> = 550; de Leon et al. 2005) ^c			
Lifetime alcohol use disorder	3.6 (2.2, 6.0)	64	52
Lifetime drug use disorder	3.1 (1.8, 5.4)	52	38
Schizophrenia	2.0 (1.3, 3.2)	28	21
High school or lower educational level	2.1 (1.3, 3.3)	71	33
Non-obesity (BMI < 30)	1.6 (2.6, 1.04)	54	17

In patients with SMI, ever smoking was defined as ever daily smoking (clinical definition). In the general population, ever smoking also included non-daily smokers, so the definition was slightly wider (epidemiological definition). A prior article described the differences and overlap between these two definitions (Diaz et al. 2009)

^aFor data from the general population, the population attributable risk was computed as $(P/100) \times (OR - 1) / \{(P/100) \times (OR - 1) + 1\}$ (Bolton and Robinson 2010)

^bBasque country is located in the North of Spain

^cIn patients with severe mental illness, the population attributable risk for a particular factor was adjusted for the other described factors. Covariate-adjusted attributable risks were computed by using Stata's `aflogit` command (StataCorp 2009; Greenland and Drescher 1993)

Table 6

Comparing the potential for genetic studies of the association of schizophrenia with increased ever daily smoking with other associations

Association	Comparison	Cultural issues	Genetic component
Association of ever daily smoking with other lifetime addictions			
Ever daily smoking with lifetime alcohol addiction	Stronger and probably consistent in Western countries Very complex with bidirectional components	Very important in alcohol use	Unknown
Ever daily smoking with lifetime drug addiction	Stronger Probably consistent in Western countries Common/specific components for each drug Confounded by alcohol use/addiction	Drug access varies by world region	Unknown
Association of severe mood disorders with ever daily smoking			
Bipolar disorder with ↑ ever daily smoking	Weaker and less consistent Possibly explained by ↑ other lifetime addictions	Subject to ceiling/floor effects ^a	No primary? ^b
Major depressive disorder with ↑ ever daily smoking	Weaker and less consistent Possibly explained by ↑ other lifetime addictions	Subject to ceiling/floor effects ^a	No primary? ^b
Association of schizophrenia with other lifetime addictions			
Schizophrenia with ↑ lifetime alcohol addiction	Weaker and less consistent Confounders not studied	Some countries no alcohol access	Unknown Complex definition ^c
Schizophrenia with ↑ lifetime drug addiction	Weaker and less consistent Bidirectional components Confounded by ↑ tobacco and alcohol use/addiction	Drug access varies by world region	Difficult to study

^aThe association between schizophrenia and increased (↑) ever daily smoking is also subject to ceiling and floor effects, but bipolar and major depressive disorders may be more susceptible to these effects (Campo-Arias et al. 2006)

^bCurrent limited information suggests that the association between bipolar/major depressive disorder with increased lifetime addictions may explain the increase in ever daily smoking seen in these severe mood disorders. Thus, studying the genes associated with bipolar/major depressive disorder with increased ever daily smoking may reveal genes contributing to the association of bipolar/major depressive disorder with increased lifetime addictions

^cTwin studies suggest that genetic effects are important in alcohol dependence (Ystrom et al. 2011). When the phenotype is modified to include other less severe phenotypes of alcohol addictions (such as those seen in people with schizophrenia), these milder forms of alcohol addiction may reflect different genetic factors (Dick et al. 2011) than those associated with alcohol dependence